(en)The present invention relates to compositions and methods of producing carotenoids and carotenoid derivatives.

1.ApplicationNumber: US-201615560951-A
1.PublishNumber: US-2018080031-A1
2.Date Publish: 20180322
3.Inventor: WANG YECHUN

4.Inventor Harmonized: WANG YECHUN(US)

5.Country: US
6.Claims:
(en)The present invention relates to compositions and methods of producing carotenoids and carotenoid derivatives.

7.Description:
(en)FIELD OF THE INVENTION
The present disclosure provides recombinant microorganisms and methods for production of carotenoids and carotenoid derivatives.
BACKGROUND OF THE INVENTION
Carotenoids, the basic source of yellow, orange and red, are among the most common, naturally occurring pigments. Carotenoids are naturally biosynthesized by bacteria, algae, fungi, and plants. Carotenoids have numerous benefits for human health and commercial utility as food flavorings, colorants, nutrient supplements, cosmetics and animal feed additives and supplements. The global market for carotenoids is growing, from $1.2 billion in 2010 to an estimated $1.4 billion by 2018 with CAGR of 2.3%. For example, β-carotene is used extensively in dietary supplements and as a colorant in food, beverage, and pharmaceutical formulations, and accounted for $261 million in 2010 and will be worth $334 million in 2018; lycopene is used for food color and food additive, dietary supplements, and accounted for $66 million in 2010 and will be worth $84 million in 2018. Carotenoids are produced commercially by chemical synthesis, extraction from natural sources, or microbial fermentation. Currently, over 90% of the market is covered by chemically synthesized carotenoids.
Products of carotenoid degradation such as α-ionone and β-ionone also have commercial importance. For instance, α-ionone and β-ionone are important fragrance chemicals that are used extensively in the perfumes and fragrance industry. In particular, α-ionone has a variety of applications, ranging from flavor and fragrance to cosmetics and pharmaceutical industries. α-ionone is an unsaturated ketone with a pleasant floral scent, and is naturally found in a variety of oils of flowers of Boronia Megastigma (Nees), renna, in violet moss and in oil of costus root, black currants, blackberries, raspberries, black tea, plum and peach. It is commonly used as a flavor agent, including in non-alcoholic beverages, ice cream, candy, gelatins and puddings, chewing gum, and as a fragrance agent in decorative cosmetics, and in nearly all perfumes.
There are three basic methods for obtaining α-ionone: 1) chemical synthesis; 2) direct extraction from a natural source; or 3) de novo biotechnological transformation, which includes microbial and enzymatic biotransformation. None of the currently available methods of producing α-ionone are satisfactory. Chemical synthesis currently dominates the global market. However, as α-ionone is a chiral compound, chemical synthesis produces a racemic mixture, (R)(+)-α-ionone and (S)(−)-α-ionone, which have different sensorial properties, and which are too costly to separate. In nature, α-ionone is found as an almost optically pure (R)(+)-enantiomer (>99%). As such, the sensorial properties of chemically produced α-ionone are not equivalent to the natural (R)(+)-α-ionone enantiomer. Additionally, chemical synthesis is environmentally unfriendly and is not accepted by consumers who like natural products.
Direct extraction from a natural source is also not very feasible. In general, the biological systems that naturally produce carotenoids are industrially intractable and/or produce the compounds at such low levels that commercial scale isolation is not practicable. For instance, plants have been an important source of natural ionones, but they carry ionones in such low amounts that the extraction is tedious and costly. The content of α-ionone is extremely low in plants, about 1.3-81 μg/kg in raspberry and blackberry. Additionally, there are no known natural biological systems capable of producing α-ionone alone. All known natural biological systems that produce ionones either produce β-ionone or a mixture of α- and β-ionone.
De novo synthesis of α-ionone is an attractive alternative for the production of α-ionone because it yields only the desirable enantiomer, is less damaging to the environment, and does not generate toxic waste. Most importantly, α-ionone produced by this method is defined as “natural” and demands a high market value. However, currently known de novo systems use enzymes from potentially harmful bacteria. Two exogenous genes (crtB and crtI) from Pantoea ananatis were used for lycopene production in Yarrowia lipolytica. Pantoea ananatis is an unconventional plant pathogen bacterium implicated in diseases of a wide range of host crops, including maize and onion, Eucalyptus , sudangrass and honeydew melons. Its implication in human infections reveals its capacity for proliferation and potential to cause disease in a vertebrate host. As such, the bacterium carries potential risks for humans and the environment, and enzymes from such bacteria that are to be used in food or medical applications are not accorded GRAS status (generally regarded as safe) for use in food or medical applications.
Therefore, there is a need for improved biological systems capable of efficiently providing natural, non-synthetic alternatives for carotenoids, and in particular the α-ionone carotenoid derivative, at a lower cost.
SUMMARY OF THE INVENTION
In one aspect, the present disclosure provides a recombinant microorganism comprising at least one nucleic acid construct encoding a lycopene cyclase enzyme selected from lycopene ε-cyclase and lycopene β-cyclase and a carotenoid cleavage dioxygenase enzyme. The nucleic acid sequences are operably linked to one or more expression control sequences. The lycopene ε-cyclase enzyme may be from Lactuca sativa . The lycopene β-cyclase may be a lycopene cyclase enzyme of a bifunctional lycopene cyclase/phytoene synthase enzyme encoded by carRP of M. circinelloides . Alternatively, the lycopene β-cyclase may be a lycopene cyclase enzyme of a bifunctional lycopene cyclase/phytoene synthase enzyme encoded by carRA of Phycomyces blakesleeanus . The carotenoid cleavage dioxygenase enzyme may be CCD1 from Daucus carota . One or more of the nucleic acid sequences of the at least one nucleic acid construct may be operably linked to an intron-containing transcriptional elongation factor TEF promoter (TEFIN). One or more of the nucleic acid sequences of the at least one nucleic acid construct may be operably linked to an export protein promoter (EXP1). One or more of the nucleic acid sequences of the at least one nucleic acid construct may be codon-optimized for expression in the microorganism. The recombinant microorganism may comprise lycopene ε-cyclase and α-ionone. Alternatively, the recombinant microorganism may comprise lycopene β-cyclase and β-ionone.
The microorganism may be Yarrowia lipolytica . When the microorganism is Yarrowia lipolytica , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Mucor circinelloides . The phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Phycomyces blakesleeanus . When the phytoene synthase enzyme is phytoene synthase of lycopene cyclase/phytoene synthase, the lycopene cyclase/phytoene synthase enzyme is modified to decrease lycopene cyclase activity. When the microorganism is Yarrowia lipolytica , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Yarrowia lipolytica , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is Yarrowia lipolytica , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Xanthophyllomyces dendrorhous , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
The microorganism may be Saccharomyces cerevisiae . When the microorganism is Saccharomyces cerevisiae , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Mucor circinelloides . The phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Phycomyces blakesleeanus . When the phytoene synthase enzyme is phytoene synthase of lycopene cyclase/phytoene synthase, the lycopene cyclase/phytoene synthase enzyme is modified to decrease lycopene cyclase activity. When the microorganism is Saccharomyces cerevisiae , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from S. cerevisiae , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is Saccharomyces cerevisiae , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from S. cerevisiae , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
The microorganism may be E. coli . When the microorganism is E. coli , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene synthase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is E. coli , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene desaturase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is E. coli , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a lycopene cyclase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is E. coli , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is E. coli , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene dehydrogenase enzyme from Mucor circinelloides , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene dehydrogenase enzyme from Phycomyces blakesleeanus , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from Yarrowia lipolytica , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Yarrowia lipolytica , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Xanthophyllomyces dendrorhous , wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme and a geranylgeranyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is Yarrowia lipolytica or Saccharomyces cerevisiae , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme and a farnesyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. When the microorganism is Yarrowia lipolytica or Saccharomyces cerevisiae , the at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme fused in frame with a farnesyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an isopentenyl diphosphate isomerase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
In another aspect, the present disclosure provides a recombinant microorganism comprising at least one nucleic acid construct comprising a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme, a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity, a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, a nucleic acid sequence encoding an enzyme selected from lycopene ε-cyclase and lycopene β-cyclase, and a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme. The geranylgeranyl diphosphate synthase enzyme may be fused in frame with the farnesyl diphosphate synthase enzyme. The recombinant microorganism may comprise lycopene ε-cyclase and α-ionone. Alternatively, the recombinant microorganism may comprise lycopene β-cyclase and β-ionone.
In yet another aspect, the present disclosure provides a recombinant microorganism comprising a nucleic acid sequence encoding a nucleic acid an acetyl-coA acetyltransferase enzyme, a nucleic acid sequence encoding a HMG-CoA reductase enzyme, a nucleic acid sequence encoding an isopentenyl diphosphate isomerase, a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme, a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity, a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, a nucleic acid sequence encoding a lycopene ε-cyclase enzyme, and a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme. The nucleic acid sequences are operably linked to one or more expression control sequences. The recombinant microorganism may comprise lycopene ε-cyclase and α-ionone. The geranylgeranyl diphosphate synthase enzyme may be fused in frame with a farnesyl diphosphate synthase enzyme.
In another aspect, the disclosure provides a recombinant microorganism comprising at least one nucleic acid construct comprising a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, a nucleic acid sequence encoding an HMG-CoA reductase enzyme, a nucleic acid sequence encoding an isopentenyl diphosphate isomerase, a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme, a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity, a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, a nucleic acid sequence encoding a lycopene ε-cyclase enzyme, and a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme. The nucleic acid sequences are operably linked to one or more expression control sequences. The microorganism may comprise lycopene α-ionone. The geranylgeranyl diphosphate synthase enzyme may be fused in frame with a farnesyl diphosphate synthase enzyme.
In an additional aspect, the disclosure provides a recombinant microorganism comprising at least one nucleic acid construct comprising a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, a nucleic acid sequence encoding an HMG-CoA reductase enzyme, a nucleic acid sequence encoding an isopentenyl diphosphate isomerase, a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme, a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme, a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, and a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme. The nucleic acid sequences are operably linked to one or more expression control sequences. The microorganism may comprise β-ionone. The geranylgeranyl diphosphate synthase enzyme may be fused in frame with a farnesyl diphosphate synthase enzyme.
In another aspect, the present disclosure also provides a recombinant microorganism comprising at least one nucleic acid construct comprising a nucleic acid sequence encoding a fusion protein comprising a farnesyl diphosphate synthase enzyme fused in frame with a geranylgeranyl diphosphate synthase enzyme, a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity, a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, and a a nucleic acid sequence encoding a lycopene ε-cyclase enzyme. The nucleic acid sequences are operably linked to one or more expression control sequences. Additionally, the farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase enzymes are from Yarrowia lipolytica , the lycopene cyclase/phytoene synthase and phytoene dehydrogenase enzymes are from Mucor circinelloides , and the lycopene ε-cyclase enzyme is from Lactuca sativa . Ane or more of the enzymes are overexpressed in the microorganism by operably linking the at least one nucleic acid sequence to an intron-containing transcriptional elongation factor TEF promoter (TEFIN).
The microorganism may comprise ε-carotene. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an HMG-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an isopentenyl diphosphate isomerase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
In another aspect, the disclosure provides a recombinant microorganism comprising at least one nucleic acid construct comprising a nucleic acid sequence encoding a fusion protein comprising a farnesyl diphosphate synthase enzyme fused in frame with a geranylgeranyl diphosphate synthase enzyme, a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme, and a nucleic acid sequence encoding a phytoene dehydrogenase enzyme. The nucleic acid sequences are operably linked to one or more expression control sequences. The farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase enzymes are from Yarrowia lipolytica , and the lycopene cyclase/phytoene synthase and phytoene dehydrogenase enzymes are from Mucor circinelloides . One or more of the enzymes are overexpressed in the microorganism by operably linking the at least one nucleic acid sequence to an intron-containing transcriptional elongation factor TEF promoter (TEFIN).
The microorganism may comprise β-carotene. The lycopene cyclase enzyme may be lycopene cyclase of bifunctional lycopene cyclase/phytoene synthase of M. circinelloides . The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an HMG-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. The at least one nucleic acid construct may further comprise a nucleic acid sequence encoding an isopentenyl diphosphate isomerase, wherein the nucleic acid sequence is operably linked to one or more expression control sequences. the at least one nucleic acid construct further encodes a geranyl pyrophosphate synthase enzyme.
In another aspect, the disclosure provides a recombinant microorganism comprising at least one nucleic acid construct comprising a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity and a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, wherein the nucleic acid sequences are operably linked to one or more expression control sequences. The microorganism may comprise lycopene.
In another aspect, the disclosure provides a method of producing α-ionone, the method comprising cultivating a recombinant microorganism of any of the recombinant microorganisms described above capable of producing α-ionone under conditions sufficient for the production of α-ionone. The method may further comprise isolating α-ionone from the recombinant microorganism.
In another aspect, the disclosure provides a method of producing β-ionone, the method comprising cultivating a recombinant microorganism of any of the recombinant microorganisms described above capable of producing α-ionone under conditions sufficient for the production of β-ionone. The method may further comprise isolating β-ionone from the recombinant microorganism.
In another aspect, the disclosure provides a method of producing ε-carotene, the method comprising cultivating a recombinant microorganism of any of the recombinant microorganisms described above capable of producing α-ionone under conditions sufficient for the production of ε-carotene. The method may further comprise isolating ε-carotene from the recombinant microorganism.
In another aspect, the disclosure provides a method of producing β-carotene, the method comprising cultivating a recombinant microorganism of any of the recombinant microorganisms described above capable of producing α-ionone under conditions sufficient for the production of β-carotene. The method may further comprise isolating β-carotene from the recombinant microorganism.
In another aspect, the disclosure provides a method of producing lycopene, the method comprising cultivating a recombinant microorganism of any of the recombinant microorganisms described above capable of producing α-ionone under conditions sufficient for the production of lycopene. The method may further comprise isolating lycopene from the recombinant microorganism.
In another aspect, the disclosure provides a nucleic acid construct comprising a nucleic acid sequence encoding a lycopene cyclase enzyme selected from lycopene ε-cyclase and lycopene β-cyclase, and a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme. The nucleic acid sequences are operably linked to one or more expression control sequences. The lycopene ε-cyclase enzyme may be from Lactuca sativa . The lycopene β-cyclase enzyme is lycopene cyclase of a bifunctional lycopene cyclase/phytoene synthase of M. circinelloides . Alternatively, the lycopene β-cyclase enzyme may be lycopene cyclase of bifunctional lycopene cyclase/phytoene synthase of Phycomyces blakesleeanus . The carotenoid cleavage dioxygenase enzyme may be CCD1 from Daucus carota . The nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene dehydrogenase enzyme. The phytoene dehydrogenase enzyme may be from Mucor circinelloides . The phytoene dehydrogenase enzyme may also be from Phycomyces blakesleeanus . The nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene synthase enzyme. The phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Mucor circinelloides . Alternatively, the phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Phycomyces blakesleeanus . When the phytoene synthase enzyme is phytoene synthase of lycopene cyclase/phytoene synthase enzyme, the lycopene cyclase/phytoene synthase enzyme is modified to decrease lycopene cyclase activity. The phytoene synthase enzyme may also be from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene desaturase enzyme from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a lycopene cyclase enzyme from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from Yarrowia lipolytica . The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from S. cerevisiae . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Yarrowia lipolytica . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Xanthophyllomyces dendrorhous . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from S. cerevisiae . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme and a geranylgeranyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme fused in frame with a farnesyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding an isopentenyl diphosphate isomerase. The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme.
The nucleic acid sequences are operably linked to one or more expression control sequences. One or more of the nucleic acid sequences may be operably linked to an intron-containing transcriptional elongation factor TEF promoter (TEFIN). Alternatively, one or more of the nucleic acid sequences may be operably linked to an export protein promoter (EXP1). The nucleic acid construct may be codon-optimized for expression in a heterologous microorganism.
REFERENCE TO COLOR FIGURES
The application file contains at least one photograph executed in color. Copies of this patent application publication with color photographs will be provided by the Office upon request and payment of the necessary fee.



BRIEF DESCRIPTION OF THE FIGURES
The following drawings form part of the present disclosure and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific aspects presented herein.
FIG. 1 . Schematic depicting the metabolic pathway from glucose to IPP and DMAPP in yeast. The pathway consists of the glycolytic pathway and mevalonate pathway. AtoB, acetoacetyl-CoA thiolase; HMGS, HMG-CoA synthase; HMGR, HMG-CoA reductase; MVK, Mevalonate kinase; PMK, Phosphomevalonate kinase, MPD, Mevalonate-5-pyrophosphate decarboxylase; IPP, Isopentenyl-pyrophosphate; DMAPP, Dimethylallyl diphosphate; IPI, IPP isomerase.
FIG. 2 . Pathway for synthesis of lycopene from IPP and DMAPP in bacteria. GPP, Geranyl diphosphate; GPPS, Geranyl diphosphate synthase; FPP, Farnesyl diphosphate; FPPS, Farnesyl diphosphate synthase; GGPP, geranylgeranyl diphosphate; GGPPS, geranylgeranyl diphosphate synthase; crtB, Phytoene synthase; crtI, Phytoene desaturase.
FIG. 3 . Reconstruction of the lycopene pathway with the genes carRP* and carB in Y. lipolytica . carRP*, Mutated phytoene synthase/lycopene cyclase; carB, Phytoene dehydrogenase.
FIG. 4 . Proposed pathway for α-ionone and β-ionone from lycopene. The linear lycopene is converted to β-carotene by carRP or lycopene β-cyclase (crtY); lycopene ε-cyclase (LCYe) add one ε-ring to lycopene to form the monocyclic β-carotene; LCYe and lycopene β-cyclase (LCYb) add a ε-ring and β-ring to β-carotene to form ε-carotene and α-carotene, respectively; oxidative enzymatic cleavage of β-carotene, ε-carotene, and α-carotene by carotenoid cleavage dioxygenase (CCD) yields β-ionone, α-ionone, and a mixture of β-ionone and α-ionone, respectively.
FIG. 5 . depicts HPLC profiles of (A) authentic lycopene (>90%; Sigma (Saint Louis, Mo.; CAT No L9879) and (B) extracts from Y. lipolytica with exogenous expression of carRP* and carB.
FIG. 6 . depicts UV spectra of authentic lycopene (A) and of samples extracted from Y. lipolytica (B).
FIG. 7 . depicts HPLC profiles showing the production of ε-carotene and β-carotene in lycopene-producing Y. lipolytica expressing lycopene ε-cyclase of Lactuca sativa (LsLCYe) at different absorption spectra, 470 nm (A), 440 nm (B) and 420 nm (C).
FIG. 8 . depicts putative UV absorption spectra of ε-carotene (A), and β-carotene (B).
FIG. 9 . depicts a photograph depicting the orange coloration of ε-carotene produced in the Y. lipolytica strain AI-004. (A) The absence of the orange color in ε-carotene-producing Y. lipolytica strain expressing the empty vector. (B) and (C) The disappearance of the orange color in ε-carotene-producing Y. lipolytica strain expressing of DcCCD1.
FIG. 10 . depicts HPLC profiles showing the production of new compounds (C14 aldehyde) in lycopene-producing Y. lipolytica expressing carotenoid cleavage dioxygenases of carrot (DcCCD1) at different absorption spectra, 470 nm (A), 440 nm (B), and 420 nm (C).
FIG. 11 . depicts an HPLC profile of putative UV absorption spectrum of C14 aldehyde.
FIG. 12 . depicts GC-chromatogram (A) and mass spectrum (B) for SPME-GC-MS analysis of α-ionone formed in Y. lipolytica engineered to accumulate ε-carotene with the expression of DcCCD1.
FIG. 13 . depicts mass spectra of authentic α-ionone (A), and of compounds in the headspace of Y. lipolytica cultures expressing DcCCD1 (B), and the comparison of authentic α-ionone and sample (C).
FIG. 14 depicts a photographic image of an agar plate showing that intron-containing promoter and FPPS::GGPPS fusion protein increases lycopene production in Y. lipolytica . Strains in the image were grown on the YPD plate for two days. (A) Y. lipolytica containing YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP*-TEF-YLGGPPS vector (AI-002); (B) Y. lipolytica containing YAL-rDNA-URA3-TEFIN-OptcarB-TEFIN-OptcarRP*-TEFIN-YLGGPPS (AI-007); (C) Strain (AI-007) containing FPPS::GGPPS fusion gene; (D) Strain (AI-002) containing FPPS::GGPPS fusion gene.
FIG. 15 . depicts a photographic image of an agar plate showing that intron-containing promoter and FPPS::GGPPS fusion protein increases β-carotene production in Y. lipolytica . Strains in the image were grown on the YPD plate for two days. (A) Y. lipolytica containing YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP-TEF-YLGGPPS vector (AI-010); (B) Y. lipolytica containing YAL-rDNA-URA3-TEFIN-OptcarB-TEFIN-OptcarRP-TEFIN-YLGGPPS (AI-008); (C) Strain (AI-008) containing FPPS::GGPPS fusion gene; and (D) Strain (AI-010) containing FPPS::GGPPS fusion gene.
FIG. 16 depicts a photographic image of an agar plate showing the expression of DcCCD1 in β-carotene-producing Y. lipolytica strain (AI-010). (A) AI-010 strain transformed with empty vector, and AI-010 strain transformed with vector expressing DcCCD1 (B) and (C).



DETAILED DESCRIPTION
The present disclosure is based in part on the discovery that industrially significant quantities of carotenoids and carotenoid products for commercial uses can desirably be produced in genetically modified microorganisms. Described herein is an engineered pathway capable of producing enatiomerically pure (R)(+)-α-ionone, which can be constructed in microorganisms. Advantageously, such a pathway produces enatiomerically pure α-ionone without the concomitant production of β-ionone. Additionally, the pathway can be constructed using nucleic acids encoding enzymes from microorganisms that do not carry any risk for humans and the environment, thereby providing a natural, safe alternative to chemical synthesis, and greater ease of isolation. As such, the present disclosure provides recombinant microorganisms encoding enzymes in a pathway for producing enatiomerically pure (R)(+)-α-ionone, and methods of using the recombinant microorganisms for producing enatiomerically pure (R)(+)-α-ionone. The invention also provides methods of producing carotenoids and carotenoid products, and methods of harvesting the carotenoids and carotenoid products.
I. Recombinant Microorganism
In one aspect, the present disclosure provides a recombinant microorganism capable of biosynthesizing one or more carotenoid or carotenoid derivatives. A recombinant microorganism of the invention comprises at least one nucleic acid construct encoding carotenoid biosynthetic enzymes. In particular, a recombinant microorganism of the present disclosure is capable of biosynthesizing industrially tractable quantities of lycopene, ε-carotenoid, β-ionone, and enantiomerically pure (R)(+)-α-ionone. The microorganism, carotenoid biosynthetic enzymes, and the genetic engineering of microorganism to produce carotenoids and carotenoid derivatives are discussed in more detail below.
(a) Microorganisms
A recombinant microorganism of the present disclosure may be any microorganism provided the microorganism is generally regarded as safe for use in food or medical applications. In general, a microorganism of the disclosure is a bacterium, a fungus, or an alga. Preferably, a microorganism of the disclosure is a bacterium or a fungus. When selecting a particular microorganism for use in accordance with the present invention, it will generally be desirable to select a microorganism whose cultivation characteristics are amendable to commercial scale production. In general, any modifiable and cultivatable microorganism may be employed.
A microorganism may be naturally capable of producing carotenoids or their derivatives. When a microorganism is naturally capable of producing carotenoids or their derivatives, the microorganism may be genetically engineered to alter expression of one or more endogenous enzymes to enhance production of carotenoids or their derivatives. In addition, when a microorganism is naturally capable of producing carotenoids or their derivatives, the microorganism may be genetically engineered to express one or more exogenous enzymes to enhance production of carotenoids or their derivatives. A microorganism may also be genetically engineered to alter expression of one or more endogenous genes, and to express one or more exogenous genes to enhance production of carotenoids or their derivatives.
A suitable microorganism may be a fungal microorganism capable of producing carotenoids or their derivatives. Fungal microorganisms that are naturally capable of producing carotenoids or their derivatives are known in the art. Non-limiting examples of genera of fungi that are naturally capable of producing carotenoids or their derivatives may include Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Marlierella, Mucor, Phycomyces, Pythium, Rhodosporidium, Rhodotorula, Trichosporon, and Yarrowia . Any fungus belonging to these genera may be utilized as host fungi according to the present invention, and may be engineered or otherwise manipulated to generate inventive, carotenoid and derivative producing fungal strains. Organisms of species that include, but are not limited to, Blakeslea trispora, Candida utilis, Candidapulcherrima, C. revkauji, C. tropicalis, Cryptococcus curvatus, Cunninghamella echinulata, C. elegans, C. japonica, Lipomyces starkeyi, L. lipoferus, Mortierella alpina, M. isabellina, M. ramanniana, M. vinacea, Mucor circinelloides, Phycomyces blakesleanus, Pythium irregulare, Rhodosporidium toruloides, Rhodotorula glutin is, R. gracilis, R. graminis, R. mucilaginosa, R. pinicola, Schizosaccharomyces pombe, Trichosporon pullans, T. cutaneum, Yarrowia lipolytica , and Xanthophyllomyces dendrorhous , may be used.
Alternatively, the fungus may not be naturally capable of producing carotenoids and derivatives of carotenoids. When the fungus is not naturally capable of producing carotenoids or their derivatives, the fungus is generally recombinant to express one or more exogenous genes to reconstruct a carotenoid biosynthetic pathway for production of carotenoids or their derivatives. Non-limiting examples of genera of fungi that are not naturally capable of producing carotenoids or their derivatives, but that may be suitable for use in the present disclosure, may include Aspergillus, Botrytis, Cercospora, Fusarium ( Gibberella ), Kluyveromyces, Neurospora, Penicillium, Pichia ( Hansenula ), Puccinia, Saccharomyces, Schizosaccharomyces, Sclerotium, Trichoderma , and Xanthophyllomyces ( Phaffia ). Organisms of species that include, but are not limited to, Aspergillus nidulans, A. niger, A. terreus, Botrytis cinerea, Cercospora nicotianae, Fusarium fujikuroi ( Gibberella zeae ), Kluyveromyces lactis, K. lactis, Neurospora crassa, Pichia pastoris, Puccinia distincta, Saccharomyces cerevisiae, Sclerotium rolfsii, Schizosaccharomyces pombe, Trichoderma reesei , and Xanthophyllomyces dendrorhous ( Phaffia rhodozyma ), may be used.
A fungal microorganism of the disclosure may be Yarrowia lipolytica . Advantages of Y. lipolytica include, for example, tractable genetics and molecular biology, availability of genomic sequence (see, for example, Sherman et al., Nucleic Acids Res. 32 (Database issue):D315-8, 2004), suitability to various cost-effective growth conditions, and ability to grow to high cell density. Furthermore, there is already extensive commercial experience with Y. lipolytica.
Saccharomyces cerevisiae is also a useful host cell in accordance with the present invention, particularly due to its experimental tractability and the extensive experience that researchers have accumulated with the organism. Although cultivation of Saccharomyces under high carbon conditions may result in increased ethanol production, this can generally be managed by process and/or genetic alterations.
Other preferred fungal microorganisms of the disclosure may be Candida utilis, Pichia pastoris, Schizosaccharomyces pombe, Blakeslea trispora , and Xanthophyllomyces dendrorhous . The edible yeast C. utilis is an industrially important microorganism approved by the U.S. Food and Drug Administration as a safe substance. Through its large-scale production, C. utilis has become a promising source of single-cell protein as well as a host for the production of several chemicals, such as glutathione. P. pastoris is another non-carotenogenic yeast that has also been studied to production of carotenoids, and it is able to grow in organic materials.
A suitable microorganism may be a bacterial microorganism capable of producing carotenoids or their derivatives. Bacterial microorganisms that are naturally capable of producing carotenoids or their derivatives are known in the art. Non-limiting examples of a bacterial microorganism capable of producing carotenoids or their derivatives may include Erwinia species, and Agrobacterium aurantiacum.
Alternatively, the bacterium may not be naturally capable of producing carotenoids and derivatives of carotenoids. Non-limiting examples of genera of bacteria that are not naturally capable of producing carotenoids or their derivatives, but that may be suitable for use in the present disclosure, may include Escherichia coli and Zymomonas mobilis. Escherichia coli and Zymomonas mobilis do not naturally synthesize carotenoids, but by using carotenogenic genes, recombinant strains of such bacteria capable of accumulating lycopene, beta-carotene, and astaxanthin have been produced.
A bacterial microorganism of the disclosure may be Escherichia coli , an intensively studied microorganism with tractable genetics that is also extensively used in industrial manufacturing for its suitability to various cost-effective growth conditions, and its ability to grow to high cell density.
(b) Enzymes and Pathways
The genes and enzymes of the carotenoid biosynthetic pathway are almost completely elucidated in plant, algae, bacteria, and fungi. In brief, carotenoid biosynthesis originates from the mevalonate (MVA) pathway shown in FIG. 1 and produces isopentenyl phosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) using acetyl-CoA as a starting compound. The pyruvate is converted into acetyl-CoA by the action of pyruvate decarboxylase (PDC), cytosolic acetyldehyde dehydrogenase (ALD), and acetyl-CoA synthetase (ACS) (Pronk et al. Yeast. 12: 1607-1633, 1996). In the cytosol, acetyl-CoA is also generated through the action of ATP-citrate lyase (ACL) from citrate. Citrate is synthesized in the mitochondria through tricarboxylic acid (TCA) cycle, and can be moved into the cytosol (in exchange for malate) by citrate/malate translocase. Carotenoid biosynthesis requires the enzymes of the mevalonate pathway, of which acetyl-CoA acetyltransferase (AtoB), HMG-CoA reductase enzyme (HMGR), and isopentenyl diphosphate isomerase (IPI) are step-limiting. As such, any recombinant microorganism of the present disclosure may be further genetically modified to express enzymes of the mevalonate pathway. In particular, a microorganism may be genetically modified to express step-limiting enzymes of the mevalonate pathway. As it will be recognized in the art, expressing step-limiting enzymes, including expressing step-limiting enzymes of the mevalonate pathway, may improve production of any metabolites dependent from compounds produced by the mevalonate pathway.
Carotenoid biosynthesis further requires geranylgeranyl diphosphate synthase (GGPPS), farnesyl diphosphate synthase (FPPS), phytoene synthase (PSases), and phytoene desaturase for the production of the C40 lycopene ( FIG. 2 and FIG. 3 ). The condensation of two GGPP molecules forming phytoene is the first committed step in the carotenoid biosynthetic pathway. For example, the expression of mutated Taxus canadensis GGPPS result in an approximately 1.7-fold increase in levopimaradiene production (See, for example, Leonard et al. PNAS, 107(31): 13654-13659, 2010).
After lycopene synthesis, further cyclases, ketolases and hydroxylases result in the production of different carotenoids from lycopene ( FIG. 4 ). Lycopene is the substrate of two competing cyclases: lycopene ε-cyclase (LCYe) and lycopene β-cyclase (LCYb). When acting together on the two ends of the molecule, LCYe and LCYb form α-carotene. The action of LCYe alone forms δ- and ε-carotene. The action of crtY/carRP alone forms γ- and β-carotene. Subsequently, the various carotenes are cleaved by carotenoid cleavage enzymes (CCDs) yielding α-ionone and β-ionone ( FIG. 4 ).
According to the present invention, carotenoid production in a host microorganism may be adjusted by modifying the expression or activity of one or more enzymes involved in carotenoid biosynthesis and carotenoid derivative biosynthesis. Such modification comprises expression of one or more heterologous nucleic acids encoding carotenoid biosynthetic enzymes and carotenoid derivative biosynthetic enzymes into the host cell. Alternatively or additionally, modifications may be made to the expression or activity of one or more endogenous or heterologous carotenoid biosynthetic enzymes and carotenoid derivative biosynthetic enzymes. Given the considerable conservation of components of the carotenoid biosynthetic enzymes, it is expected that heterologous carotenoid biosynthetic enzymes and carotenoid derivative biosynthetic enzymes will often function even in significantly divergent organisms. Furthermore, should it be desirable to introduce more than one heterologous carotenoid biosynthetic enzyme or carotenoid derivative biosynthetic enzyme, in many cases polypeptides from different source organisms will function together. A plurality of different heterologous carotenoid biosynthetic enzymes and carotenoid derivative biosynthetic enzymes may be expressed in the same host cell. This plurality contains only polypeptides from the same source organism (e.g., two or more sequences of, or sequences derived from, the same source organism). The plurality includes polypeptides independently selected from different source organisms (e.g., two or more sequences of, or sequences derived from, at least two independent source organisms).
In general, a microorganism is genetically engineered to produce or increase production of lycopene from which all other carotenoids and carotenoid derivatives are produced, to produce or increase production of one or more carotenoids (for example, produce or increase production of ε-carotene), to shift production from one carotenoid (e.g., α-carotene) to another (e.g., ε-carotene), to produce or increase production of one or more carotenoid derivatives (for example, α-ionone), to shift production from one carotenoid derivative (e.g., β-ionone) to another (e.g., α-ionone), or combinations thereof. Introduction of one or more carotenogenic modifications (e.g., increased expression of one or more endogenous or heterologous carotenogenic polypeptides), in accordance with the present invention, can achieve these goals. For instance, a microorganism of the present disclosure may be genetically engineered to express any one or more of pyruvate decarboxylase, cytosolic acetyldehyde dehydrogenase, acetyl-CoA synthetase, ATP-citrate lyase, acetoacetyl-CoA thiolase, HMG-CoA synthase, 3-hydroxy-3-methylglutaryl-CoA reductase, Mevalonate kinase, Phosphomevalonate kinase, Mevalonate pyrophosphate decarboxylase, Isopentenyl diphosphate isomerase, farnesyl pyrophosphate synthase, geranylgeranyl pyrophosphate synthase, phytoene synthase, phytoene desaturase, lycopene β-cyclase, lycopene ε-cyclase, and one or more carotenoid cleavage dioxygenases.
The genetic modifications for producing, increasing production, or shifting production of carotenoids and carotenoid derivatives described herein are described further below. A genetically modified microorganism may encode any of the carotenoid enzymes, but with some further modifications designed to enhance production of the carotenoid or carotenoid derivative.
As described above, the selection of the organism of origin of the enzyme may be important and is preferably an organism generally regarded as safe. Non-limiting examples of organisms of origin of metabolic enzymes that may be regarded as safe include Mucor circinelloides, Phycomyces blakesleeanus, Y. lipolytica, Saccharomyces cerevisiae, Candida utilis, Pichia pastoris , and Schizosaccharomyces pombe.
A. Lycopene
A microorganism of the present disclosure may be genetically engineered to produce or increase production of lycopene. As shown in FIGS. 2 and 3 , biosynthetic enzymes of lycopene synthesis starts with IPP and DMAPP and require the activity of geranyl pyrophosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (PSase), and phytoene dehydrogenase enzymes. As such, a microorganism of the present disclosure may be genetically engineered to express any combination of one or more of the lycopene biosynthetic enzymes. For instance, a microorganism may be genetically engineered to express geranyl pyrophosphate synthase, farnesyl diphosphate synthase, geranylgeranyl diphosphate synthase, phytoene synthase, and phytoene dehydrogenase. Alternatively, a microorganism of the present disclosure may be genetically engineered to express any combination of one or more of geranyl pyrophosphate synthase, farnesyl diphosphate synthase, geranylgeranyl diphosphate synthase, phytoene synthase, and phytoene dehydrogenase.
The choice of lycopene biosynthetic enzyme or combination of biosynthetic enzymes that are expressed in a microorganism can and will vary depending on the specific microorganism host cell or strain, and its ability to produce lycopene. For instance, when the microorganism is Y. lipolytica , a recombinant Y. lipolytica may express geranyl pyrophosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (PSase), and phytoene dehydrogenase. Preferably, when the microorganism is Y. lipolytica , the Y. lipolytica microorganism is a recombinant microorganism expressing phytoene synthase (PSase), and phytoene dehydrogenase. Also preferred when the microorganism is Y. lipolytica , a recombinant Y. lipolytica expresses farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (PSase), and phytoene dehydrogenase. As explained above, a recombinant Y. lipolytic may further express enzymes of the MVA pathway.
Preferably, when a recombinant microorganism is Y. lipolytica phytoene synthase (PSase) and phytoene dehydrogenase enzymes are encoded by M. circinelloides , which is an organism generally regarded as safe. M. circinelloides is a β-carotene-producing filamentous fungus, and the biosynthetic pathway of carotenoid biosynthesis is well characterized. The M. circinelloides genes encoding PSase and phytoene dehydrogenase have been isolated. The carB gene of M. circinelloides (SEQ ID NO: 58) encodes a phytoene dehydrogenase enzyme (SEQ ID NO: 61). Preferably, the codon-optimized carB gene of M. circinelloides encoded by SEQ ID NO: 59 is used as a source of the phytoene dehydrogenase enzyme for producing lycopene.
The carRP gene of M. circinelloides (SEQ ID NO: 62) encodes an enzyme comprising two domains (SEQ ID NO: 64): the P domain determines phytoene synthase activity, and the R domain is responsible for lycopene cyclase activity which cyclizes lycopene to γ-carotene. The R domain is functional even in the absence of the P domain, while the P domain needs the proper R domain conformation to carry out its function. Preferably, when the carRP gene of M. circinelloides is used as a source of the PSase enzyme activity for producing lycopene, the carRP gene is modified to decrease or inhibit lycopene cyclase activity (carRP*) (SEQ ID NO: 65). As used herein, the term “decrease or inhibit” refer to a substantial or complete elimination of the activity of an enzyme such as lycopene cyclase. As such, decreasing or inhibiting the lycopene cyclase activity of the carRP gene of M. circinelloides prevents or substantially reduces the cyclization of the lycopene to γ-carotene, and ensures the accumulation of lycopene in the microorganism. More preferred, the codon-optimized modified carRP gene of M. circinelloides (carRP*) encoded by SEQ ID NO: 66 is used as a source of the PSase enzyme activity for producing lycopene.
Alternatively, the carRA gene of Phycomyces blakesleeanus (SEQ ID NO: 67), which is homologous to the carRP gene of M. circinelloides , may also be used. As with the carRP gene of M. circinelloides , modifying the carRA gene of P. blakesleeanus to express an enzyme with modifications to the amino acids 77 or 215 of the R domain produces an enzyme deficient in lycopene cyclase activity.
Also preferred, when a recombinant microorganism is Y. lipolytica expressing farnesyl diphosphate synthase (FPPS), a recombinant Y. lipolytica expresses FPPS of Y. lipolytica . More preferably, FPPS of Y. lipolytica is encoded by nucleic acid sequence of SEQ ID NO: 72.
When a recombinant microorganism is Y. lipolytica expressing geranylgeranyl diphosphate synthase (GGPPS), a recombinant Y. lipolytica preferably expresses GGPPS of Y. lipolytica . More preferably, GGPPS of Y. lipolytica is encoded by nucleic acid sequences SEQ ID NO: 70. Alternatively, a recombinant Y. lipolytica preferably expresses GGPPS of Xanthophyllomyces dendrorhous.
Also preferred, when a recombinant microorganism is Y. lipolytica expressing farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), a recombinant Y. lipolytica expresses FPPS and GGPPS enzymes of Y. lipolytica . More preferably, FPPS and GGPPS enzymes of Y. lipolytica are encoded by nucleic acid sequences SEQ ID NO: 72 and SEQ ID NO: 70, respectively.
Further modifications of genes and enzymes expressed in a microorganism designed to enhance production of the carotenoid or carotenoid derivatives may also be used. For instance, when FPPS and GGPPS are expressed in a recombinant microorganism of the disclosure, FPPS to GGPPS may be fused to increase production of geranyl geraniol, thereby enhancing production of lycopene and other carotenoids and their derivatives. As such it is preferred that when a recombinant microorganism is Y. lipolytica expressing farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), the recombinant Y. lipolytica expresses a fusion of FPPS and GGPPS. Preferably, when a recombinant microorganism is Y. lipolytica expressing farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), the recombinant Y. lipolytica expresses a fusion of FPPS and GGPPS of SEQ ID NO: 74 encoded by SEQ ID NO: 73.
When the microorganism is S. cerevisiae , a recombinant S. cerevisiae may express 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), geranyl pyrophosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (PSase), and phytoene dehydrogenase. Preferably, when a microorganism is S. cerevisiae , the microorganism is a recombinant S. cerevisiae expressing phytoene synthase (PSase), and phytoene dehydrogenase. Also preferred when the microorganism is S. cerevisiae , a recombinant S. cerevisiae expresses geranyl pyrophosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (PSase), and phytoene dehydrogenase. Most preferred when the microorganism is S. cerevisiae , a recombinant S. cerevisiae expresses geranyl pyrophosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (PSase), and phytoene dehydrogenase. As explained above, a recombinant S. cerevisiae may further express enzymes of the MVA pathway.
Preferably, when a recombinant microorganism is S. cerevisiae , phytoene synthase (PSase) and phytoene dehydrogenase are the PSase and phytoene dehydrogenase enzymes of M. circinelloides . Preferably, the carB gene of M. circinelloides encoded by SEQ ID NO: 58 is used as a source of the phytoene dehydrogenase enzyme for producing lycopene. More preferred, the codon-optimized carB gene of M. circinelloides encoded by SEQ ID NO: 60 is used as a source of the phytoene dehydrogenase enzyme for producing lycopene.
Also preferably when a recombinant microorganism is S. cerevisiae , the modified carRP* gene of M. circinelloides encoded by SEQ ID NO: 65 is used as a source of the phytoene synthase enzyme for producing lycopene. More preferred, the codon-optimized modified carRP* gene of M. circinelloides encoded by SEQ ID NO: 68 is used as a source of the phytoene synthase enzyme for producing lycopene. The carRA gene of Phycomyces blakesleeanus (SEQ ID NO: 67) may also be used when a recombinant microorganism is S. cerevisiae.
Also preferred, when a recombinant microorganism is S. cerevisiae , the recombinant S. cerevisiae expresses the FPPS and GGPPS enzymes of S. cerevisiae . More preferably, the FPPS and GGPPS enzymes of S. cerevisiae are encoded by nucleic acid sequences SEQ ID NO: 75 and SEQ ID NO: 77, respectively. More preferred when a recombinant microorganism is S. cerevisiae , the recombinant S. cerevisiae expresses a fusion of FPPS and GGPPS. Preferably, when a recombinant microorganism is S. cerevisiae expressing farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), the recombinant S. cerevisiae expresses a fusion of FPPS and GGPPS of SEQ ID NO: 80 encoded by SEQ ID NO: 79.
Also preferred, when a recombinant microorganism is S. cerevisiae , the recombinant S. cerevisiae expresses the 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) enzyme of S. cerevisiae . More preferably, the HMGR enzyme of S. cerevisiae is a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase (tHMG1). More preferred when a recombinant microorganism is S. cerevisiae , the recombinant S. cerevisiae expresses a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase of SEQ ID NO: 82 encoded by SEQ ID NO: 81.
When a microorganism is E. coli , a recombinant E. coli capable of producing lycopene may express geranylgeranyl pyrophosphate synthase, phytoene synthase, and phytoene desaturase, and phytoene cyclase. Preferably, the geranylgeranyl pyrophosphate synthase, phytoene synthase, and phytoene desaturase, are from Erwinia herbicola.
B. Carotene
A microorganism of the present disclosure may be genetically engineered to produce or increase production of one or more carotenoids. Alternatively, a microorganism of the present disclosure may be genetically engineered to shift production from one carotenoid to another.
As shown in FIG. 4 , lycopene is the substrate of two competing cyclases: lycopene ε-cyclase (LCYe) and lycopene β-cyclase (LCYb). When acting together on the two ends of the molecule, lycopene ε-cyclase and lycopene β-cyclase form α-carotene. The action of lycopene ε-cyclase alone forms δ- and ε-carotene. The action of lycopene β-cyclase alone forms γ- and β-carotene. As such, a microorganism of the present disclosure may be genetically engineered to express any combination of lycopene ε-cyclase and lycopene β-cyclase to produce one or a combination of carotenes. For instance, a microorganism of the present disclosure may be genetically engineered to produce β-carotene, γ-carotene, β-carotene, α-carotene, or ε-carotene. Alternatively, a microorganism may be genetically engineered to produce a combination of β-carotene, γ-carotene, β-carotene, α-carotene, or ε-carotene. As such, a microorganism of the present disclosure may be genetically engineered to express lycopene ε-cyclase, lycopene β-cyclase, or a combination of lycopene ε-cyclase and lycopene β-cyclase.
Preferably, a microorganism of the present disclosure is genetically engineered to express lycopene ε-cyclase to produce ε-carotene. A microorganism may preferably be genetically engineered to express lycopene ε-cyclase of Lactuca sativa . A microorganism may more preferably be genetically engineered to express lycopene ε-cyclase of Lactuca sativa having SEQ ID NO: 87. When a recombinant microorganism is Y. lipolytica , lycopene ε-cyclase of Lactuca sativa having SEQ ID NO: 87 is encoded by nucleic acid SEQ ID NO: 84 codon-optimized for expression in Y. lipolytica.
Also preferred, a recombinant microorganism of the present disclosure is genetically engineered to express lycopene β-cyclase to produce β-carotene. A recombinant microorganism may preferably express lycopene cyclase of the bifunctional lycopene cyclase/phytoene synthase of M. circinelloides (carRP). More preferably, a recombinant microorganism expresses lycopene cyclase of the wild-type bifunctional lycopene cyclase/phytoene synthase of M. circinelloides (carRP). When a recombinant microorganism is Y. lipolytica , lycopene cyclase of the wild-type bifunctional lycopene cyclase/phytoene synthase of M. circinelloides is encoded by nucleic acid SEQ ID NO: 63 codon-optimized for expression in Y. lipolytica.
When a microorganism is E. coli , a recombinant E. coli capable of producing ε- or β-carotene may express geranylgeranyl pyrophosphate synthase, phytoene synthase, phytoene desaturase, and phytoene cyclase. Preferably, a recombinant E. coli capable of producing β-carotene expresses geranylgeranyl pyrophosphate synthase, phytoene synthase, phytoene desaturase, and lycopene cyclase of Erwinia herbicola . Also preferred is a recombinant E. coli capable of producing ε-carotene expresses geranylgeranyl pyrophosphate synthase, phytoene synthase, and phytoene desaturase of Erwinia herbicola , and lycopene ε-cyclase of Lactuca sativa (SEQ ID NO:86).
It will be recognized that the genetic modifications described herein for producing the various carotenoids may be in addition to any or all of the genetic modifications described above for producing lycopene.
C. Carotene Derivatives
A microorganism of the present disclosure may be genetically engineered to produce or increase production of a carotenoid derivative. In particular, a microorganism may be genetically engineered to produce or increase production of the α- and β-ionone cleavage products of carotenes. Preferably, a microorganism is genetically engineered to produce or increase production of the α-ionone cleavage product of carotenes.
The cleavage reactions of carotenes are generally catalyzed by a class of non-heme iron enzymes known as carotenoid cleavage dioxygenases (CCDs; FIG. 4 ). As such, a microorganism of the present disclosure is genetically engineered to express any combination of one or more of CCD1 and CCD4 to produce α-ionone or β-ionone. Irrespective of the carotenoid cleavage dioxygenase used in a microorganism of the disclosure, it is preferred that the CCD is not able to cleave acyclic carotenoids, such as lycopene and phytoene.
FIG. 4 also shows that cleavage of γ-carotene and β-carotene by a CCD enzyme produces β-ionone, cleavage of α-carotene by a CCD enzyme produces a combination of α-ionone and β-ionone, and cleavage of ε-carotene by a CCD enzyme produces α-ionone. As such, depending on the intended use of a recombinant microorganism in producing α-ionone, β-ionone, or a combination of α-ionone and β-ionone, the microorganism may further be genetically engineered to produce the carotene that may be cleaved into α-ionone, β-ionone, or a combination of α-ionone and β-ionone.
A microorganism may further genetically engineered to produce ε-carotene that is cleaved into α-ionone. When the intended use of a microorganism of the present disclosure is genetically engineered to produce α-ionone, but not β-ionone, the microorganism may further be engineered to inhibit expression of lycopene β-cyclase, or is naturally not able to express lycopene β-cyclase, to prevent production of β-ionone.
Alternatively, a microorganism may further be genetically engineered to produce β-carotene that is cleaved into β-ionone. When the intended use of a microorganism of the present disclosure is genetically engineered to produce β-ionone, but not α-ionone, the microorganism may further be engineered to inhibit expression of lycopene α-cyclase, or is naturally not able to express lycopene α-cyclase, to prevent production of α-ionone.
CCDs constitute a large enzyme family and typically exhibit a high degree of region-specificity to the double bond positions of their carotenoid substrates. The CCD enzymes are grouped in CCD1, CCD4, CCD7, and CCD8 classes and can cleave multiple carotenoid substrates while producing various volatile compounds. In general, CCD1 and CCD4 are able to cleave the 5,6 (5,6′), 7,8 (7′,8′) and 9,10 (9′,10′) double bonds of a wide range of carotenoids. In comparison, CCD7 and CCD8 are involved in the biosynthesis of strigolactone growth regulators. The 9′, 10′ bond of β-carotene is cleaved by CCD7, yielding β-ionone (C 13 ) and 10′-apo-β-carotenal. The latter compound is subsequently cleaved and cyclized by CCD8 into a bioactive strigolactone precursor named carlactone. α-ionone is the proposed reaction product of the cleavage of the 9,10 (9′10′) double bond of α-carotene. As such, a microorganism of the present disclosure may be genetically engineered to express any combination of one or more carotenoid cleavage dioxygenase enzymes. Preferably, a microorganism of the present disclosure is genetically engineered to express any combination of one or more carotenoid cleavage dioxygenase enzymes capable of cleaving a carotenoid to produce α-ionone, β-ionone, or a combination of α-ionone and β-ionone.
Preferably, a microorganism of the present disclosure is genetically engineered to express CCD1 from Daucus carota (SEQ ID NO: 88). When a recombinant microorganism is Y. lipolytica , CCD1 from Daucus carota is encoded by nucleic acid SEQ ID NO: 89 codon-optimized for expression in Y. lipolytica . When a recombinant microorganism is S. cerevisiae , CCD1 from Daucus carota is encoded by nucleic acid SEQ ID NO: 90 codon-optimized for expression in S. cerevisiae.
It will further be recognized that the genetic modifications described herein for producing the various carotenoid derivatives may be in addition to any or all of the genetic modifications described above for producing lycopene and carotenoids.
(c) Genetic Engineering
According to the present invention, carotenoid production in a host organism may be adjusted by expressing or modifying the expression or activity of one or more proteins involved in carotenoid biosynthesis. Such modification may involve introduction of at least one nucleic acid construct comprising one or more nucleic acid sequences encoding heterologous carotenoid biosynthesis polypeptides into the host microorganism. Alternatively or additionally, modifications may be made to the expression or activity of one or more endogenous or heterologous carotenoid biosynthesis polypeptides. Given the considerable conservation of components of the carotenoid biosynthesis polypeptides, it is expected that heterologous carotenoid biosynthesis polypeptides will often function even in significantly divergent organisms. Furthermore, should it be desirable to introduce more than one heterologous carotenoid biosynthesis polypeptide, in many cases polypeptides from different source organisms will function together.
At least one nucleic acid construct encoding a plurality of different heterologous carotenoid biosynthesis polypeptides may be introduced into the same host cell. A plurality of different heterologous carotenoid biosynthesis polypeptides may comprise only polypeptides from the same source organism (e.g., two or more sequences of, or sequences derived from the same source organism). Alternatively, a plurality of different heterologous carotenoid biosynthesis polypeptides may comprise polypeptides independently selected from different source organisms (e.g., two or more sequences of, or sequences derived from, at least two independent source organisms).
Those of ordinary skill in the art will appreciate that the selection of a particular microorganism for use in accordance with the present invention will also affect, for example, the selection of expression sequences utilized with any heterologous polypeptide to be introduced into the cell, and will also influence various aspects of culture conditions, etc. Much is known about the different gene regulatory requirements, protein targeting sequence requirements, and cultivation requirements of different host cells to be utilized in accordance with the present invention (see, for example, with respect to Yarrowia , Barth et al. FEMS, Microbiol Rev. 19:219, 1997; Madzak et al., J. Biotechnol. 109:63, 2004; see, for example, with respect to Xanthophyllomyces , Verdoes et al., Appl Environ Microbiol 69: 3728-38, 2003; Visser et al. FEMS Yeast Res 4: 221-31, 2003; Martinez et al., Antonie Van Leeuwenhoek. 73(2):147-53, 1998; Kim et al. Appl Environ Microbiol. 64(5):1947-9, 1998; Wery et al., Gene 184(1):89-97, 1997; see, for example, with respect to Saccharomyces , Guthrie and Fink, Methods in Enzymology 194:1-933, 1991). In certain aspects, for example, targeting sequences of the host cell (or closely related analogs) may be useful to include for directing heterologous proteins to subcellular localization. Thus, such useful targeting sequences can be added to heterologous sequences for proper intracellular localization of activity. In other aspects (e.g., addition of mitochondrial targeting sequences), heterologous targeting sequences may be eliminated or altered in the selected heterologous sequences (e.g., alteration or removal of source organism plant chloroplast targeting sequences).
As described above, a recombinant microorganism of the present disclosure comprises at least one nucleic acid construct comprising one or more nucleic acid sequences encoding a carotenoid biosynthesis enzyme. A nucleic acid sequence of the present disclosure may be operably linked to one or more expression control sequences for expressing a carotenoid biosynthesis enzyme. “Expression control sequences” are regulatory sequences of nucleic acids, or the corresponding amino acids, such as promoters, leaders, enhancers, introns, recognition motifs for RNA, or DNA binding proteins, polyadenylation signals, terminators, internal ribosome entry sites (IRES), secretion signals, subcellular localization signals, and the like, that have the ability to affect the transcription or translation, or subcellular, or cellular location of a coding sequence in a host cell. Exemplary expression control sequences are described in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990).
A recombinant microorganism may synthesize one, two, three, four, five, or more carotenoid biosynthetic enzymes. A one or more nucleic acid encoding any of the enzymes disclosed herein may be chromosomally integrated, or may be expressed on an extrachromosomal vector. Suitable vectors are known in the art. Similarly, methods of chromosomally inserting a nucleic acid are known in the art. For additional details, see the Examples.
A large number of promoters, including constitutive, promoters for high-level expression (overexpression), inducible and repressible promoters, from a variety of different sources are well known in the art. Representative sources include, for example, viral, mammalian, insect, plant, yeast, and bacterial cell types, and suitable promoters from these sources are readily available, or can be made synthetically based on sequences publicly available on line or, for example, from depositories such as the ATCC as well as other commercial or individual sources. Promoters can be unidirectional (i.e., initiate transcription in one direction) or bi-directional (i.e., initiate transcription in either a 3′ or 5′ direction).
Non-limiting examples of suitable promoters may include an intron-containing transcriptional elongation factor TEF promoter (TEFIN), GPAT (glycerol-3-phosphate o-acyl transferase), YAT1 (ammonium transporter), EXP1 (export protein), and GPD (glyceraldehyde-3-phosphate dehydrogenase), FBA1 (fructose 1,6-bisphosphate aldolase), GPM1 (phosphoglycerate mutase), FBA1IN (FBA1 containing an intron), the GAL promoters of yeast, and hp4d (Four tandem copies of upstream activator sequences (UAS1B) fragment from pXPR2 and a minimal pLEU2 fragment. Preferably, a promoter suitable for overexpression of proteins is used to overexpress one or more carotenoid biosynthesis enzymes of the disclosure. Non-limiting examples of suitable promoters for overexpression of proteins include intron-containing transcriptional elongation factor TEF promoter (TEFIN) and EXP1 (export protein).
A nucleic acid may be modified for high-level expression (overexpression) in a microorganism of the invention. As used herein, “modified” refers to an alteration of a nucleic acid sequence that results in a change in the level of transcription of a nucleic acid sequence, or that results in a change in the level of synthesis of an encoded protein. For instance, the term “modify” may refer to altering the start codon of a nucleic acid sequence. Modify may also refer to fusing two enzymes to increase the activity of each enzyme. Alternatively, modify may refer to optimizing the codons of the nucleic acid sequence to alter the level of translation of the mRNA. For instance, non-A rich codons initially after the start codon of a nucleic acid sequence may not maximize translation of the corresponding mRNA. Modify may refer to altering the GC content of the nucleic acid sequence to change the level of translation of the corresponding mRNA. Additionally, modify may refer to alterations in the DNA sequence of a gene so that the transcribed mRNA is stabilized with a reduced rate of degradation but still able to specify a protein of the original amino acid sequence. Alternatively, a nucleic acid may be optimized by altering the nucleic acid such that the ability of the encoded protein to form efficient enzyme complexes is affected. Preferably, the codons of the nucleic acid sequence are altered so as to mimic the codons in genes encoding highly synthesized proteins of a particular organism.
A nucleic acid of the invention may further comprise at least one marker. Generally speaking, a marker encodes a product that the host cell cannot make, such that the cell acquires resistance to a specific compound, is able to survive under specific conditions, or is otherwise differentiable from cells that do not carry the marker. Markers may be positive or negative markers. A nucleic acid of the invention may comprise both a positive marker and a negative marker. The marker may code for an antibiotic resistance factor, or a nutritional requirement. Additionally, fluorescent proteins may be used as visually identifiable markers. Generally speaking, markers may be present during construction of the strains, but are typically removed from the final constructs. Proteins can also be marked by adding a sequence such as FLAG, HA, His tag, that can be recognized by a monoclonal antibody using immunological methods.
Nucleic acid constructs of the invention may also comprise flanking sequences. The phrase “flanking sequence” as used herein, refers to a nucleic acid sequence homologous to a chromosomal sequence. A construct comprising a flanking sequence on either side of a construct (i.e., a left flanking sequence and a right flanking sequence) may homologously recombine with the homologous chromosome, thereby integrating the construct between the flanking sequences into the chromosome. Generally speaking, flanking sequences may be of variable length. Preferably, the flanking sequences may be between about 300 and about 500 bp. Alternatively, the left flanking sequence and the right flanking sequence may be substantially the same length. For more details, see the Examples.
As such, the present disclosure provides in part a nucleic acid construct comprising a nucleic acid sequence encoding a lycopene cyclase enzyme selected from lycopene ε-cyclase and lycopene β-cyclase, and a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme. The lycopene ε-cyclase enzyme may be from Lactuca sativa . The lycopene β-cyclase enzyme is lycopene cyclase of a bifunctional lycopene cyclase/phytoene synthase of M. circinelloides . Alternatively, the lycopene β-cyclase enzyme may be lycopene cyclase of bifunctional lycopene cyclase/phytoene synthase of Phycomyces blakesleeanus . The carotenoid cleavage dioxygenase enzyme may be CCD1 from Daucus carota . The nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene dehydrogenase enzyme. The phytoene dehydrogenase enzyme may be from Mucor circinelloides . The phytoene dehydrogenase enzyme may also be from Phycomyces blakesleeanus . The nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene synthase enzyme. The phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Mucor circinelloides . Alternatively, the phytoene synthase enzyme may be phytoene synthase of lycopene cyclase/phytoene synthase from Phycomyces blakesleeanus . When the phytoene synthase enzyme is phytoene synthase of lycopene cyclase/phytoene synthase enzyme, the lycopene cyclase/phytoene synthase enzyme is modified to decrease lycopene cyclase activity. The phytoene synthase enzyme may also be from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a phytoene desaturase enzyme from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a lycopene cyclase enzyme from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from Yarrowia lipolytica . The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from S. cerevisiae . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Yarrowia lipolytica . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Xanthophyllomyces dendrorhous . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from S. cerevisiae . The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Erwinia herbicola . The nucleic acid construct may further comprise a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme and a geranylgeranyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme fused in frame with a farnesyl diphosphate synthase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme. The nucleic acid construct may further comprise a nucleic acid sequence encoding an isopentenyl diphosphate isomerase. The nucleic acid construct may further comprise a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme.
The nucleic acid sequences are operably linked to one or more expression control sequences. One or more of the nucleic acid sequences may be operably linked to an intron-containing transcriptional elongation factor TEF promoter (TEFIN). Alternatively, one or more of the nucleic acid sequences may be operably linked to an export protein promoter (EXP1). The nucleic acid construct may be codon-optimized for expression in a heterologous microorganism.
A nucleic acid construct of the invention may comprise a plasmid suitable for use in a microorganism of choice. Such a plasmid may contain multiple cloning sites for ease in manipulating nucleic acid sequences. Numerous suitable plasmids are known in the art.
II. Methods
In another aspect, the present disclosure provides a method of producing carotenoids and carotenoid derivatives. Preferably, a method of the present disclosure is capable of producing lycopene, carotene, and ionones. Most preferred are methods of producing α-ionone and β-ionone.
A method of the disclosure comprises cultivating a recombinant microorganism expressing carotenoid biosynthesis enzymes under conditions sufficient for the production of the carotenoid or carotenoid derivative. A recombinant microorganism may be as described in Section I above.
As discussed above, production of carotenoids and carotenoid derivatives in a recombinant microorganism of the present disclosure generally comprises cultivating the relevant organism under conditions sufficient to accumulate a carotenoid or carotenoid derivative, harvesting the modified microorganism, and isolating the carotenoid or carotenoid microorganism from the harvested microorganism.
Methods of cultivating a microorganism are well known in the art and may be similar to conventional fermentation methods. As will be appreciated by a skilled artisan, the culture conditions sufficient to accumulate a carotenoid or carotenoid derivative can and will vary depending on the specific microorganism host cell or strain and the carotenoid or carotenoid derivative produced by the microorganism. A recombinant microorganism may be cultured in a medium comprising a carbon source, a nitrogen source, and minerals, and if necessary, appropriate amounts of nutrients which the microorganism requires for growth. As the carbon source, saccharides such as glucose, fructose, sucrose, molasses and starch hydrolysate, organic acids such as fumaric acid, citric acid and succinic acid, or alcohol such as ethanol and glycerol may be used. As the nitrogen source, various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean-hydrolysate, or digested fermentative microorganism may be used. As minerals, potassium monophosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, calcium chloride, and the like may be used. As vitamins, thiamine, yeast extract, and the like, may be used. The pH of the medium may be between about 5 and about 9. When the microorganism comprises a mutation that limits the production of an essential nutrient, the medium may be supplemented with the essential nutrient to maintain growth of the microorganism.
When the microorganism is Y. lipolytica or S. cerevisiae , the recombinant microorganism may be cultivated in YPD medium (10 g/L yeast extract, 20 g/L peptone and 20 g/L glucose) to produce a carotenoid or carotenoid derivative of the disclosure. Y. lipolytica or S. cerevisiae may also be cultivated in SD-dropout medium containing 1.7 g/L yeast nitrogen base without amino acids and ammonium sulphate, 20 g/L D-glucose, 5 g/L ammonium sulphate, 2 g/L yeast synthetic drop-out medium supplements and other nutrients that may vary depending on the nutrient requirement of the Y. lipolytica or S. cerevisiae strain.
Various temperature and duration of cultivation may also be used and will vary depending on the specific microorganism host cell or strain, the carotenoid or carotenoid derivative produced by the microorganism, and its culture conditions. The cultivation may be performed under aerobic conditions, such as by shaking and/or stirring with aeration. When the microorganism is Y. lipolytica or S. cerevisiae , a recombinant microorganism may be cultivated at a temperature of about 20 to about 40° C., preferably at a temperature of about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, and about 40° C. More preferably, a recombinant Y. lipolytica or S. cerevisiae may be cultivated at a temperature of about 28° C.
A recombinant microorganism of the present disclosure may be cultivated for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days before isolating carotenoids and carotenoid derivatives. Preferably, when a recombinant microorganism is Y. lipolytica , the recombinant microorganism is cultivated for about 1, 2, or 3 days before isolating carotenoids and carotenoid derivatives, preferably, 1 day.
When a recombinant microorganism is E. coli , the microorganism may be cultivated in LB medium in a shaker at a temperature of about 25 to about 40° C., preferably at a temperature of about 37° C. If carotenogenic enzymes expressed in E. coli are under the control of an inducible promoter, the enzymes may be induced at a temperature of about 25 to 35° C., preferably at a temperature of about 30° C.
Methods and systems for isolating carotenoids and carotenoid derivatives have been established for a wide variety of carotenoids and carotenoid derivatives (see, for example, Perrut M, Ind Eng Chem Res, 39: 4531-4535, 2000, the disclosure of which is incorporated herein in its entirety). In brief, cells are typically recovered from culture, often by spray drying, filtering or centrifugation. In some instances, cells are homogenized and then subjected to supercritical liquid extraction or solvent extraction (e.g., with solvents such as chloroform, hexane, methylene chloride, methanol, isopropanol, ethyl acetate, etc.) using conventional techniques.
Given the sensitivity of carotenoids generally to oxidation, the disclosure may employ oxidative stabilizers (e.g., tocopherols, vitamin C; ethoxyquin; vitamin E, BHT, BHA, TBHQ, etc, or combinations thereof) during and/or after carotenoid isolation. Alternatively or additionally, microencapsulation, for example with proteins, may be employed to add a physical barrier to oxidation and/or to improve handling (see, for example, U.S. Patent Application 2004/0191365).
In general, a recombinant microorganism accumulate carotenoids and carotenoid de rivatives to levels that are greater than at least about 0.1% of the dry weight of the cells. The total carotenoid accumulation in a recombinant microorganism may be to a level at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20% or more of the total dry weight of the cells.
III. Various Aspects of the Invention




1. A recombinant microorganism comprising at least one nucleic acid construct comprising:
(a) a nucleic acid sequence encoding a lycopene cyclase enzyme selected from lycopene ε-cyclase and lycopene β-cyclase; and (b) a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences.

2. The microorganism of claim 1 wherein the microorganism is Yarrowia lipolytica.
3. The microorganism of claim 1 wherein the microorganism is Saccharomyces cerevisiae.
4. The microorganism of claim 1 , wherein the microorganism is E. coli.
5. The microorganism of any one of the preceding claims, wherein one or more of the nucleic acid sequences of the at least one nucleic acid construct is operably linked to an intron-containing transcriptional elongation factor TEF promoter (TEFIN).
6. The microorganism of any one of the preceding claims, wherein one or more of the nucleic acid sequences of the at least one nucleic acid construct is operably linked to an export protein promoter (EXP1).
7. The microorganism of any one of the preceding claims, wherein one or more of the nucleic acid sequences of the at least one nucleic acid construct is codon-optimized for expression in the microorganism.
8. The microorganism of any one of the preceding claims, wherein the lycopene ε-cyclase enzyme is from Lactuca sativa.
9. The microorganism of any one of the preceding claims, wherein the lycopene β-cyclase is a lycopene cyclase enzyme of a bifunctional lycopene cyclase/phytoene synthase encoded by carRP of M. circinelloides.
10. The microorganism of any one of the preceding claims, wherein the lycopene β-cyclase is a lycopene cyclase enzyme of a bifunctional lycopene cyclase/phytoene synthase encoded by carRA of Phycomyces blakesleeanus.
11. The microorganism of any one of the preceding claims, wherein the carotenoid cleavage dioxygenase enzyme is CCD1 from Daucus carota.
12. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
13. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene dehydrogenase enzyme from Mucor circinelloides , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
14. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene dehydrogenase enzyme from Phycomyces blakesleeanus , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
15. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
16. The microorganism of any one of the preceding claims, wherein the phytoene synthase enzyme is phytoene synthase of lycopene cyclase/phytoene synthase from Mucor circinelloides.
17. The microorganism of any one of the preceding claims, wherein the phytoene synthase enzyme is phytoene synthase of lycopene cyclase/phytoene synthase from Phycomyces blakesleeanus.
18. The microorganism of any one of the preceding claims, wherein the phytoene synthase enzyme is lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity.
19. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene synthase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
20. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene desaturase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
21. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a lycopene cyclase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
22. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
23. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from Yarrowia lipolytica , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
24. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from S. cerevisiae , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
25. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
26. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Yarrowia lipolytica , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
27. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Xanthophyllomyces dendrorhous , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
28. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from S. cerevisiae , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
29. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
30. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme and a geranylgeranyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
31. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme fused in frame with a farnesyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
32. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
33. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
34. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
35. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an isopentenyl diphosphate isomerase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
36. The microorganism of any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
37. The microorganism of any one of the preceding claims, comprising lycopene ε-cyclase and α-ionone.
38. The microorganism of any one of the preceding claims, comprising lycopene β-cyclase and β-ionone.
39. A recombinant microorganism comprising at least one nucleic acid construct comprising:
(a) a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme; (b) a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme; (c) a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity; (d) a nucleic acid sequence encoding a phytoene dehydrogenase enzyme; (e) a nucleic acid sequence encoding an enzyme selected from lycopene ε-cyclase and lycopene β-cyclase; and (f) a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences.

40. The microorganism of claim 39 , wherein the geranylgeranyl diphosphate synthase enzyme is fused in frame with the farnesyl diphosphate synthase enzyme.
41. The microorganism of claim any one of the preceding claims, comprising lycopene ε-cyclase and α-ionone.
42. The microorganism of claim any one of the preceding claims, comprising lycopene β-cyclase and β-ionone.
43. A recombinant microorganism comprising at least one nucleic acid construct comprising:
(a) a nucleic acid sequence encoding a nucleic acid an acetyl-coA acetyltransferase enzyme; (b) a nucleic acid sequence encoding a HMG-CoA reductase enzyme; (c) a nucleic acid sequence encoding an isopentenyl diphosphate isomerase; (d) a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme; (e) a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme; (f) a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme; (g) a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity; (h) a nucleic acid sequence encoding a phytoene dehydrogenase enzyme; (i) a nucleic acid sequence encoding a lycopene ε-cyclase enzyme; and (j) a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences.

44. The microorganism of claim 43 , comprising lycopene α-ionone.
45. The microorganism of claim any one of the preceding claims, wherein the geranylgeranyl diphosphate synthase enzyme is fused in frame with a farnesyl diphosphate synthase enzyme.
46. A recombinant microorganism comprising at least one nucleic acid construct comprising:
(a) a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme; (b) a nucleic acid sequence encoding an HMG-CoA reductase enzyme; (c) a nucleic acid sequence encoding an isopentenyl diphosphate isomerase; (d) a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme; (e) a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme; (f) a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme; (g) a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme; (h) a nucleic acid sequence encoding a phytoene dehydrogenase enzyme; and (j) a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences.

47. The microorganism of claim 46 , comprising β-ionone.
48. The microorganism of claim any one of the preceding claims, wherein the geranylgeranyl diphosphate synthase enzyme is fused in frame with a farnesyl diphosphate synthase enzyme.
49. A recombinant microorganism comprising at least one nucleic acid construct comprising:
(a) a nucleic acid sequence encoding a fusion protein comprising a farnesyl diphosphate synthase enzyme fused in frame with a geranylgeranyl diphosphate synthase enzyme; (b) a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity; (c) a nucleic acid sequence encoding a phytoene dehydrogenase enzyme; and (d) a nucleic acid sequence encoding a lycopene ε-cyclase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences; wherein the farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase enzymes are from Yarrowia lipolytica , the lycopene cyclase/phytoene synthase and phytoene dehydrogenase enzymes are from Mucor circinelloides , and the lycopene ε-cyclase enzyme is from Lactuca sativa ; and wherein one or more of the enzymes are overexpressed in the microorganism by operably linking the at least one nucleic acid sequence to an intron-containing transcriptional elongation factor TEF promoter (TEFIN).

50. The microorganism of claim 49 , comprising ε-carotene.
51. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
52. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an HMG-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
53. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an isopentenyl diphosphate isomerase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
54. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
55. A recombinant microorganism comprising at least one nucleic acid construct comprising:
(a) a nucleic acid sequence encoding a fusion protein comprising a farnesyl diphosphate synthase enzyme fused in frame with a geranylgeranyl diphosphate synthase enzyme; (b) a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme; and (c) a nucleic acid sequence encoding a phytoene dehydrogenase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences; wherein the farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase enzymes are from Yarrowia lipolytica , and the lycopene cyclase/phytoene synthase and phytoene dehydrogenase enzymes are from Mucor circinelloides ; and wherein one or more of the enzymes are overexpressed in the microorganism by operably linking the at least one nucleic acid sequence to an intron-containing transcriptional elongation factor TEF promoter (TEFIN).

56. The microorganism of claim 55 , comprising β-carotene.
57. The microorganism of claim any one of the preceding claims, wherein the lycopene β-cyclase enzyme is lycopene cyclase of bifunctional lycopene cyclase/phytoene synthase of M. circinelloides.
58. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
59. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an HMG-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
60. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding an isopentenyl diphosphate isomerase, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
61. The microorganism of claim any one of the preceding claims, wherein the at least one nucleic acid construct further comprises a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
62. A recombinant microorganism comprising at least one nucleic acid construct comprising:
(a) a nucleic acid sequence encoding a lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity; and (b) a nucleic acid sequence encoding a phytoene dehydrogenase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences.

63. The microorganism of claim 62 , comprising lycopene.
64. A method of producing α-ionone, the method comprising cultivating a recombinant microorganism of any of claim 1 , 39 , or 43 under conditions sufficient for the production of α-ionone.
65. The method of claim 64 , further comprising isolating α-ionone from the recombinant microorganism.
66. A method of producing β-ionone, the method comprising cultivating a recombinant microorganism of any of claim 1 , 39 , or 43 under conditions sufficient for the production of β-ionone.
67. The method of claim 64 , further comprising isolating β-ionone from the recombinant microorganism.
68. A method of producing ε-carotene, the method comprising cultivating a recombinant microorganism of claim 49 under conditions sufficient for production of the ε-carotene.
69. The method of claim 68 , further comprising isolating ε-carotene from the recombinant microorganism.
70. A method of producing β-carotene, the method comprising cultivating a recombinant microorganism of claim 55 under conditions sufficient for the production of the β-carotene.
71. The method of claim 70 , further comprising isolating β-carotene from the recombinant microorganism.
72. A method of producing lycopene, the method comprising cultivating a recombinant microorganism of claim 62 under conditions sufficient for the production of lycopene.
73. The method of claim 72 , further comprising isolating lycopene from the recombinant microorganism.
74. A nucleic acid expression construct comprising:
(a) a nucleic acid sequence encoding a lycopene cyclase enzyme selected from lycopene ε-cyclase and lycopene β-cyclase; and (b) a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme; wherein the nucleic acid sequences are operably linked to one or more expression control sequences.

75. The nucleic acid construct of claim 74 , wherein the nucleic acid sequences are operably linked to an intron-containing transcriptional elongation factor TEF promoter (TEFIN).
76. The nucleic acid construct of claim 74 , wherein the nucleic acid sequences are operably linked to an export protein promoter (EXP1).
77. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct is codon-optimized for expression in a heterologous microorganism.
78. The nucleic acid construct of claim any one of the preceding claims, wherein the lycopene ε-cyclase enzyme is from Lactuca sativa.
79. The nucleic acid construct of claim any one of the preceding claims, wherein the lycopene β-cyclase enzyme is lycopene cyclase of a bifunctional lycopene cyclase/phytoene synthase of M. circinelloides.
80. The nucleic acid construct of claim any one of the preceding claims, wherein the lycopene β-cyclase enzyme is lycopene cyclase of bifunctional lycopene cyclase/phytoene synthase of Phycomyces blakesleeanus.
81. The nucleic acid construct of claim any one of the preceding claims, wherein the carotenoid cleavage dioxygenase enzyme is CCD1 from Daucus carota.
82. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene dehydrogenase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
83. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene dehydrogenase enzyme from Mucor circinelloides , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
84. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene dehydrogenase enzyme from Phycomyces blakesleeanus , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
85. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
86. The nucleic acid construct of claim any one of the preceding claims, wherein the phytoene synthase enzyme is lycopene cyclase from lycopene cyclase/phytoene synthase from Mucor circinelloides.
87. The nucleic acid construct of claim any one of the preceding claims, wherein the phytoene synthase enzyme is lycopene cyclase from lycopene cyclase/phytoene synthase from Phycomyces blakesleeanus.
88. The nucleic acid construct of claims any one of the preceding claims, wherein the phytoene synthase enzyme is lycopene cyclase/phytoene synthase enzyme modified to decrease lycopene cyclase activity.
89. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene synthase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
90. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a phytoene desaturase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
91. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a lycopene cyclase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
92. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
93. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from Yarrowia lipolytica , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
94. The nucleic acid construct of claim any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme from S. cerevisiae , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
95. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
96. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Yarrowia lipolytica , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
97. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Xanthophyllomyces dendrorhous , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
98. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from S. cerevisiae , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
99. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme from Erwinia herbicola , wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
100. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a farnesyl diphosphate synthase enzyme and a geranylgeranyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
101. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a geranylgeranyl diphosphate synthase enzyme fused in frame with a farnesyl diphosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
102. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding an acetyl-coA acetyltransferase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
103. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
104. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
105. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding an isopentenyl diphosphate isomerase, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.
106. The nucleic acid construct of any one of the preceding claims, wherein the nucleic acid construct further comprises a nucleic acid sequence encoding a geranyl pyrophosphate synthase enzyme, wherein the nucleic acid sequence is operably linked to one or more expression control sequences.




Definitions
When introducing elements of the present disclosure, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements. The use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.
Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms as used herein and in the claims shall include pluralities and plural terms shall include the singular.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges can independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
The terms “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or 2 standard deviations, from the mean value. Alternatively, “about” can mean plus or minus a range of up to 20%, preferably up to 10%, more preferably up to 5%.
The term “carotenogenic modification”, as used herein, refers to a modification of a host organism that adjusts production of one or more carotenoids or their derivatives, as described herein. For example, a carotenogenic modification may increase the production level of one or more carotenoids or their derivatives, and/or may alter relative production levels of different carotenoids or their derivatives. In principle, an inventive carotenogenic modification may be any chemical, physiological, genetic, or other modification that appropriately alters production of one or more carotenoids or their derivatives in a host organism produced by that organism as compared with the level produced in an otherwise identical organism not subject to the same modification. However, the carotenogenic modification may comprise a genetic modification, typically resulting in increased production of one or more selected carotenoids or their derivatives.
The term “carotenogenic polypeptide”, as used herein, refers to any polypeptide that is involved in the process of producing carotenoids or their derivatives in a cell, and may include polypeptides that are involved in processes other than carotenoid production but whose activities affect the extent or level of production of one or more carotenoids or their derivatives, for example by scavenging a substrate or reactant utilized by a carotenoid polypeptide that is directly involved in carotenoid production. Carotenogenic polypeptides include isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, and isoprenoid biosynthesis competitor polypeptides.
The term “carotenoid” is understood in the art to refer to a structurally diverse class of pigments derived from isoprenoid pathway intermediates. The commitment step in carotenoid biosynthesis is the formation of phytoene from geranylgeranyl pyrophosphate. Carotenoids can be acyclic or cyclic, and may or may not contain oxygen, so that the term carotenoids include both carotenes and xanthophylls.
The term “isoprenoid biosynthesis polypeptide” refers to any polypeptide that is involved in the synthesis of isoprenoids. For example, as discussed herein, acetoacetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, IPP isomerase, FPP synthase, and GGPP synthase, are all involved in the mevalonate pathway for isoprenoid biosynthesis. Each of these proteins is also an isoprenoid biosynthesis polypeptide for purposes of the present invention.
The “isoprenoid pathway” is understood in the art to refer to a metabolic pathway that either produces or utilizes the five-carbon metabolite isopentyl pyrophosphate (IPP). As discussed herein, two different pathways can produce the common isoprenoid precursor IPP, the “mevalonate pathway” and the “non-mevalonate pathway”.
As used herein, the terms “cell,” “cells,” “cell line,” “host cell,” and “host cells,” are used interchangeably and encompass a variety of yeast or fungal strains that may be utilized as host strains to produce carotenoids and their derivatives. Thus, the terms “transformants” and “transfectants” include the primary subject cell and cell lines derived therefrom without regard for the number of transfers.
The term “expression” as used herein refers to transcription and/or translation of a nucleotide sequence within a host cell. The level of expression of a desired product in a host cell may be determined on the basis of either the amount of corresponding mRNA that is present in the cell, or the amount of the desired polypeptide encoded by the selected sequence. For example, mRNA transcribed from a selected sequence can be quantified by Northern blot hybridization, ribonuclease RNA protection, in situ hybridization to cellular RNA or by PCR. Proteins encoded by a selected sequence can be quantified by various methods including, but not limited to, e.g., ELISA, Western blotting, radioimmunoassays, immunoprecipitation, assaying for the biological activity of the protein, or by immunostaining of the protein followed by FACS analysis.
The term “expression cassette” refers to a nucleic acid comprising the coding sequence of a selected gene and regulatory sequences preceding (expression control sequences) and following (non-coding sequences) the coding sequence that are required for expression of the selected gene product. Thus, an expression cassette is typically composed of: (1) a promoter sequence; (2) a coding sequence (i.e., ORF); and (3) a 3′ untranslated region (i.e., a terminator) that, in eukaryotes, usually contains a polyadenylation site. The expression cassette(s) is usually included within a vector to facilitate cloning and transformation. Different expression cassettes can be transformed into different organisms including bacteria, yeast, plants and mammalian cells, as long as the correct regulatory sequences are used for each host.
“Expression control sequences” are regulatory sequences of nucleic acids, or the corresponding amino acids, such as promoters, leaders, enhancers, introns, recognition motifs for RNA, or DNA binding proteins, polyadenylation signals, terminators, internal ribosome entry sites (IRES), secretion signals, subcellular localization signals, and the like, that have the ability to affect the transcription or translation, or subcellular, or cellular location of a coding sequence in a host cell. Exemplary expression control sequences are described in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990).
A “gene” is a sequence of nucleotides which code for a functional gene product. Generally, a gene product is a functional protein. However, a gene product can also be another type of molecule in a cell, such as RNA (e.g., a tRNA or an rRNA). A gene may also comprise expression control sequences (i.e., non-coding) as well as coding sequences and introns. The transcribed region of the gene may also include untranslated regions including introns, a 5′-untranslated region (5′-UTR) and a 3′-untranslated region (3′-UTR).
The term “heterologous” refers to a nucleic acid or protein which has been introduced into an organism (such as a plant, animal, or prokaryotic cell), or a nucleic acid molecule (such as chromosome, vector, or nucleic acid construct), which is derived from another source, or which is from the same source but is located in a different (i.e., non-native) context.
The term “homology” describes a mathematically based comparison of sequence similarities which is used to identify genes or proteins with similar functions or motifs. The nucleic acid and protein sequences of the present invention can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members, related sequences or homologs. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the invention.
To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and BLAST) can be used.
The term “homologous” refers to the relationship between two proteins that possess a “common evolutionary origin”, including proteins from superfamilies (e.g., the immunoglobulin superfamily) in the same species of animal, as well as homologous proteins from different species of animal (for example, myosin light chain polypeptide, etc.; see Reeck et al., (1987) Cell, 50:667). Such proteins (and their encoding nucleic acids) have sequence homology, as reflected by their sequence similarity, whether in terms of percent identity or by the presence of specific residues or motifs and conserved positions.
As used herein, the term “increase” or the related terms “increased”, “enhance” or “enhanced” refers to a statistically significant increase. For the avoidance of doubt, the terms generally refer to at least a 10% increase in a given parameter, and can encompass at least a 20% increase, 30% increase, 40% increase, 50% increase, 60% increase, 70% increase, 80% increase, 90% increase, 95% increase, 97% increase, 99% or even a 100% increase over the control value.
The term “isolated,” when used to describe a protein or nucleic acid, means that the material has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with research, diagnostic or therapeutic uses for the protein or nucleic acid, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. The protein or nucleic acid may be purified to at least 95% homogeneity as assessed by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated protein includes protein in situ within recombinant cells, since at least one component of the protein of interest's natural environment will not be present. Ordinarily, however, isolated proteins and nucleic acids will be prepared by at least one purification step.
The terms “operably linked”, “operatively linked,” or “operatively coupled” as used interchangeably herein, refer to the positioning of two or more nucleotide sequences or sequence elements in a manner which permits them to function in their intended manner. A nucleic acid molecule according to the invention may include one or more DNA elements capable of opening chromatin and/or maintaining chromatin in an open state operably linked to a nucleotide sequence encoding a recombinant protein. A nucleic acid molecule may additionally include one or more DNA or RNA nucleotide sequences chosen from: (a) a nucleotide sequence capable of increasing translation; (b) a nucleotide sequence capable of increasing secretion of the recombinant protein outside a cell; (c) a nucleotide sequence capable of increasing the mRNA stability, and (d) a nucleotide sequence capable of binding a trans-acting factor to modulate transcription or translation, where such nucleotide sequences are operatively linked to a nucleotide sequence encoding a recombinant protein. Generally, but not necessarily, the nucleotide sequences that are operably linked are contiguous and, where necessary, in reading frame. However, although an operably linked DNA element capable of opening chromatin and/or maintaining chromatin in an open state is generally located upstream of a nucleotide sequence encoding a recombinant protein, it is not necessarily contiguous with it. Operable linking of various nucleotide sequences is accomplished by recombinant methods well known in the art, e.g., using PCR methodology, by ligation at suitable restriction sites, or by annealing. Synthetic oligonucleotide linkers or adaptors can be used in accord with conventional practice if suitable restriction sites are not present.
The terms “polynucleotide,” “nucleotide sequence” and “nucleic acid” are used interchangeably herein, and refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. In addition, a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer. A nucleic acid molecule can take many different forms, e.g., a gene or gene fragment, one or more exons, one or more introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches. As used herein, a polynucleotide includes not only naturally occurring bases such as A, T, U, C, and G, but also includes any of their analogs or modified forms of these bases, such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of sugar analogs, and modified and/or alternative backbone structures, such as polyamides.
A “promoter” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3′ direction) coding sequence. As used herein, the promoter sequence is bounded at its 3′ terminus by the transcription initiation site and extends upstream (5′ direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. A transcription initiation site (conveniently defined by mapping with nuclease S1) can be found within a promoter sequence, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the −10 and −35 consensus sequences.
The term “transformation” or “transfection” refers to the transfer of one or more nucleic acid molecules into a host cell or organism. Methods of introducing nucleic acid molecules into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, scrape loading, ballistic introduction, or infection with viruses or other infectious agents.
“Transformed”, “transduced”, or “transgenic” in the context of a cell, refers to a host cell or organism into which a recombinant or heterologous nucleic acid molecule (e.g., one or more DNA constructs or RNA, or siRNA counterparts) has been introduced. The nucleic acid molecule can be stably expressed (i.e. maintained in a functional form in the cell for longer than about three months) or non-stably maintained in a functional form in the cell for less than three months (i.e. is transiently expressed). For example, “transformed,” “transformant,” and “transgenic” cells have been through the transformation process and contain foreign nucleic acid. The term “untransformed” refers to cells that have not been through the transformation process.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; Current Protocols in Molecular Biology, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, In Situ Hybridization: Principles and Practice; Oxford University Press; M. J. Gait (Editor), 1984, Oligonucleotide Synthesis: A Practical Approach, Irl Press; D. M. J. Lilley and J. E. Dahlberg, 1992, Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology, Academic Press; Buchanan et al., Biochemistry and Molecular Biology of Plants, Courier Companies, USA, 2000; Miki and Iyer, Plant Metabolism, 2 nd Ed. D. T. Dennis, D H Turpin, D D Lefebrve, D G Layzell (eds) Addison Wesly, Langgmans Ltd. London (1997); and Lab Ref: A Handbook of Recipes, Reagents, and Other Reference Tools for Use at the Bench, Edited Jane Roskams and Linda Rodgers, 2002, Cold Spring Harbor Laboratory, ISBN 0-87969-630-3. Each of these general texts is herein incorporated by reference.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods, compositions, reagents, cells, similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are described herein.
The publications discussed above are provided solely for their disclosure before the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
Examples
The following examples are included to demonstrate the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors to function well in the practice of the disclosure. Those of skill in the art should, however, in light of the present disclosure, appreciate that many changes could be made in the disclosure and still obtain a like or similar result without departing from the spirit and scope of the disclosure, therefore all matter set forth is to be interpreted as illustrative and not in a limiting sense.
Example 1. Construction of Y. lipolytica Expression Vectors
NEB Turbo Competent E. coli (F′ proA + B + laclq ΔlacZM15/fhuA2 Δ(lac-proAB) glnV galK16 galE15 R(zgb-210::Tn10) Tet S endA1 thi-1 Δ(hsdS-mcrB)5) for cloning was purchased from New England Biolabs (Ipswich, Mass.). Cells were grown on LB medium with carbenicillin (100 mg/L) for plasmid selection. The Yarrowia lipolytica strain, CLIB138 (MatB, leu2-35, lys5-12, ura3-18, xpr2LYS5), was purchased from CIRM-Levures (Thiverval-grignon, France) and used as host cells in the following exemplifications. The strain Po1g of Yarrowia lipolytica (MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2) was used for genomic DNA extraction.
All DNA manipulations were performed according to standard procedures. Restriction enzymes and T4 DNA Ligase were purchased from New England Biolabs (Ipswich, Mass.). All PCR amplification and cloning reactions were performed using Phusion® High-Fidelity DNA Polymerase from New England Biolabs (Ipswich, Mass.).
Genomic DNA of Y. lipolytica Po1g was extracted as follows: a single colony was isolated and grown in 3 ml liquid YPD culture overnight at 30° C., then pelleted by centrifugation. The resulting pellet was washed once with 1 ml sterile water and suspended in 500 μl of lysis buffer (100 mM Tris, pH 8.0, 50 mM EDTA, 1% SDS). Cells were disrupted by adding 200 μl of glass beads (425-600 μm diameter) and vortexing for 2 minutes. The liquid phase was recovered into a fresh tube, and 275 μl of 7 M Ammonium acetate (pH 7.0) was added. The sample was incubated for 5 minutes at 65° C., put on ice for 5 min, then extracted with 500 μl of chloroform, vortexed, centrifuged for 5 min. The resulting supernatant was transferred to a new tube, and nucleic acid was precipitated with 1 ml of isopropanol and incubated at room temperature for 5 min. DNA was pelleted with centrifugation (15,000 g) for 5 minutes. Supernatant was then removed, and the pellet washed once with 70% ethanol, then dried and dissolved in 200 μl of water. 1 μl of the DNA was used for PCR.
Y. lipolytica expression vector was constructed as follows: Marker gene orotidine 5′-phosphate decarboxylase (URA3) containing LOXP site was obtained by PCR amplification with primers LOXP-URA3-Ndel-sphlF (SEQ ID NO: 1) and LOXP-URA3-AflIII-EcoRIR (SEQ ID NO: 2) using Y. lipolytica genomic DNA as template. The resulting 1.2 kb URA3 fragment was cloned into the Ndel and AMII restriction sites of the pUC57 vector to generate the YAL-URA3 construct.
A TEF promoter-XPR2 terminator cassette was constructed by stitching two nucleic acid fragments by PCR amplification. First, a 406 bp nucleic acid fragment comprising the TEF promoter was amplified using Y. lipolytica genomic DNA as a template, and the primers TEF-EcoRI-PmeIF (SEQ ID NO: 3) and TEF::XPR2-R (SEQ ID NO: 4). A 134 pb nucleic acid fragment comprising the XPR2 terminator was also amplified using Y. lipolytica genomic DNA as a template, and the primers TEF::XPR2-F (SEQ ID NO: 5) and XPR2-AflIII-SalIR (SEQ ID NO: 6). The amplified fragments comprising the TEFpromoter and the XPR2 terminator were then stitched by combining the amplified fragments, and using the combined amplified fragments as templates for amplification of the TEF-XPR2 cassette with oligonucleotide primers TEF-EcoRI-PmeIF (SEQ ID NO: 3) and XPR2-AflIII-SalIR (SEQ ID NO: 6). The cassette was then cloned into the EcoRI/AflIII restriction sites of the YAL-URA3 vector to generate the YAL-URA3-TEF-XPR2 construct.
A nucleic acid fragment comprising the LEU2 marker gene encoding 3-isopropylmalate dehydrogenase activity was amplified from the pYLEX1 vector with primers LEU2-SphIF (SEQ ID NO: 7) and LEU2-PmeIR (SEQ ID NO: 8). The LEU2 fragment was then cloned into the SphI and PmeI restriction sites of the YAL-URA3-TEF-XPR2 vector to yield the YAL-LEU2-TEF-XPR2 vector. The Y. lipolytica autonomously replicating sequence 18 (ARS18) was amplified using primers ARS18-NdeIF (SEQ ID NO: 9) and ARS19-SphIR (SEQ ID NO: 10), and cloned into the Ndel/SphI sites of the YAL-LEU2-TEF-XPR2 vector, to generate vector YAL-LEU2-TEF-XPR2-ARS. The Cre Recombinase gene (Cre) was amplified by primers Cre-BcIIF (SEQ ID NO: 11) and Cre-XmaIR (SEQ ID NO: 12) using Cre-LOXP mice genomic DNA as template, then digested with BcII and XmaIR, and cloned into BamHI/XmaI sites of YAL-LEU2-TEF-XPR2-ARS vector, to yield the YAL-LEU2-Cre vector.
A 572 bp nucleic acid fragment comprising the recombination site rDNA1 and a 822 bp nucleic acid fragment comprising the recombination site rDAN2 were amplified using primers rDNA-Ndel-NotI-SacIIF (SEQ ID NO: 13) and rDNA-SphIR (SEQ ID NO: 14), and rDNA-SalI-ASCIIF (SEQ ID NO: 15) and rDNA-AfIIII-NotI-SacIIR (SEQ ID NO: 16), respectively, using Y. lipolytica genomic DNA as a template. The nucleic acid fragment comprising rDNA1 was then cloned into the Ndel/SphI restriction sites of the YAL-URA3-TEF-XPR2 construct to yield YAL-rDNA1-URA3-TEF-XPR2, and the nucleic acid fragment comprising rDNA2 was cloned into the SalI and AMII restriction sites of YAL-rDNA1-URA3-TEF-XPR2 to form the YAL-rDNA-URA3-TEF-XPR2 construct.
Example 2: Production of Lycopene in Genetically Modified Y. lipolytica Expressing Phytoene Dehydrogenase (carB) and Modified Lycopene Cyclase/Phytoene Synthase (carRP*)
The Y. lipolytica strains were grown at 28° C. in a shaker at 250 rpm in YPD medium (10 g/L yeast extract, 20 g/L peptone and 20 g/L glucose) or in SD-dropout medium containing 1.7 g/L yeast nitrogen base without amino acids & ammonium sulphate, 20 g/L D-glucose, 5 g/L ammonium sulphate, 2 g/L yeast synthetic drop-out medium supplements (US biological, Swampscott, Mass.). Depending on the nutrient requirement of the Y. lipolytica strain, 20 mg/L histidine, 100 mg/L leucine, 50 mg/L tryptophan, or 40 mg/L uracil were added into the growth medium. Culture plates comprised 20 g/L agar.
Transformation of Y. lipolytica
Carrier DNA was purchased from Clontech, Inc. (Mountain View, Calif.) and boiled 5 minutes before using. Transformation of Y. lipolytica was performed using a modified Yarrowia transformation method (Chen, 1997). In brief, a single Yarrowia colony was spread on a YPD or SD-dropout selection plate and incubated for 12-16 hrs at room temperature. Cells were scraped from the surface of the agar and dispersed in 100 μl transformation buffer (45% PEG 4000, 100 mM lithium acetate pH 6.0, 100 mM DTT). Then about 20-100 ng plasmid (1-5 μl) and 25 μg single-stranded carrier DNA (10 mg/ml) were added. The transformation solution was thoroughly mixed and incubated at 39° C. for 60 min. The mixture was then spread on a SD-dropout selective plate and incubated at 28° C. The transformed colonies appeared after 24 hrs.
Generation of a Modified Bifunctional Enzyme Lycopene Cyclase/Phytoene Synthase (carRP*)
A nucleotide fragment (SEQ ID NO: 62) encoding a bifunctional lycopene cyclase/phytoene synthase (SEQ ID NO: 64) from Mucor circinelloides (carRP) codon-optimized for expression in Y. lipolytica was generated. The codon-optimized Mucor circinelloides carRP (SEQ ID NO: 63) was referred to as OptcarRP-. OptcarRP was cloned into the pUC57 vector to generate the pUC57-carRP plasmid. Site-directed mutagenesis was then used to introduce two mutations into OptcarRP.
The 78 th amino acid was mutated from lysine (K) to glutamate (E) using primers OptcarRP-78F (SEQ ID NO: 35) and OptcarRP-78R (SEQ ID NO: 36). In short, a PCR reaction mixture containing (10 μl) composed of Phusion HF buffer containing 20 ng pUC57-carRP template, 200 μM dNTPS, 0.5 μM forward primers, 0.5 μM reverse primers, and 0.1 μl polymerase was prepared. The PCR was performed by denaturing at 98° C. for 10 sec, annealing at 60° C. for 30 sec, and followed by elongation at 72 C for 2 min for 22 cycles. The PCR product was digested with 1 μl DpnI at 37° C. for 5 hrs to remove the template plasmid, and an aliquot of (2 μl) digested products was added to 50 μl NEB Turbo competent cells and incubated on ice for 15 min. The cell/nucleic acid mixture was then heat shocked at 42° C. for 30 sec, followed by incubation on ice for 1 min. Then, 250 μl LB medium was added and the cells were incubated at 37° C. for 1 hr, then spread on LB agar plates containing carbenicillin (100 mg/I). The identity of the mutation was confirmed by sequencing, and the resulting construct was referred to as pUC57-carRP-78. The proline (P) at amino acid 216 of mutant OptcarRP in pUC57-carRP-78 plasmid was also mutated to serine (S) using the method described here and primers OptcarRP-216F (SEQ ID NO: 37) and OptcarRP-216R (SEQ ID NO: 38). The double mutated gene was named carRP* (SEQ ID NO: 66) and encoded a lycopene cyclase/phytoene synthase enzyme comprising the K78E and P216S amino acid changes (SEQ ID NO: 69) to reduce lycopene cyclase activity.
Construction of Lycopene Biosynthetic Pathway Plasmids
The pathway of lycopene biosynthesis was reconstituted in Y. lipolytica by over-expressing three enzymes: phytoene dehydrogenase (SEQ ID NO: 61) from the carB gene of Mucor circinelloides (SEQ ID NO: 58), modified bifunctional lycopene cyclase/phytoene synthase (SEQ ID NO: 69) (carRP*) from Mucor circinelloides (SEQ ID NO: 65), and geranylgeranyl diphosphate synthase (GGPPS) from Y. lipolytica (SEQ ID NO: 71). Codon-optimized nucleic acid fragments encoding OptcarB (SEQ ID NO: 59) and OptcarRP* (SEQ ID NO: 66) were cloned and expressed in Y. lipolytica . The three genes, OptcarB (SEQ ID NO: 59), OptcaRP* (SEQ ID NO: 66), and YLGGPPS (SEQ ID NO: 70), flanked with BamHI and AvrII, were amplified by PCR using the primers, optcarB-BamHIF (SEQ ID NO: 17) and OptcarB-AvrIIR (SEQ ID NO: 18), OptcarRP*-BamHIF (SEQ ID NO: 19) and OptcarRP*-AvrIIR (SEQ ID NO: 20), and YLGGPPS-BamHIF (SEQ ID NO: 21) and YLGGPPS-AvrIIR (SEQ ID NO: 23), respectively. The three nucleotide fragments were then digested with BamHI/AvrII and ligated to the BamHI/AvrII-digested YAL-rDNA-URA3-TEF-XPR2 vector to form the plasmids YAL-rDNA-URA3-TEF-OptcarB, YAL-rDNA-URA3-TEF-OptcarRP*, and YAL-rDNA-URA3-TEF-YLGGPPS, respectively.
TEF-OptcarRP*-XPR2 and TEF-YLGGPPS-XPR2 cassettes were obtained by PCR amplification with primers PromTEF-SalIF (SEQ ID NO: 24) and TermXPR2-ASCIR (SEQ ID NO: 26) and PromTEF-ASCIF (SEQ ID NO: 25) and TermXPR2-ASCIR (SEQ ID NO: 26), respectively. First, the TEF-OptcarRP*-XPR2 was cloned into the SalI/AscI restriction sites of the YAL-rDNA-URA3-TEF-OptcarB vector to generate the YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP* plasmid. Second, YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP* was digested using AscI and treated with Antarctic Phosphatase following the manufacturer's manual (New England Biolabs, Ipswich, Mass.). The amplified AscI-digested TEF-YLGGPPS-XPR2 cassette was then cloned into the AscI-digested YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP* to generate YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP*-TEF-YLGGPPS.
Expression of Lycopene Biosynthetic Pathway Genes and Marker Excision
Y. lipolytica CLIB138 was transformed with YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP*-TEF-YLGGPPS that had been linearized with NotI. The Ura+ transformants were identified by colour screening and HPLC analysis. The strain was subsequently transformed with YAL-LEU-Cre for URA3 marker excision. The transformants were then selected for Leu + phenotypes on YNB SD minus Leucine medium (SD-LEU) plate. Single colonies were grown in 2 ml YPD medium for 24 hrs at 28° C., then 3 μl cells were grown in 3 ml YPD medium for 12 h at 28° C. The YAL-LEU-Cre-transformed cells were then streaked on YPD plates and incubated for 48 hrs at 28° C. The loss of YAL-LEU-Cre and the URA3 marker gene was confirmed on SD plates lacking leucine (SD-LEU), SD minus uracil (SD-URA), and YPD plates. After 24 hrs, pink colonies which didn't grow on both SD-LEU and SD-URA were used for subsequent transformation.
Extraction of Lycopene from Y. lipolytica
Y. lipolytica cultures were grown in 5 ml YPD medium in 50 ml test tube at 28° C. for 4 days. Cells were harvested by centrifugation at 4000 rpm for 10 min, and then suspended in extraction solution (methyl-t-butyl ether:methanol:ethyl acetate (40:50:10)). Cells were lysed by vortexing for 3 min in the presence of 300 μl glass beads. The extract was collected after centrifugation, and the extraction procedure was repeated three times.
HPLC Analysis of Lycopene
The HPLC analysis of lycopene was carried out using an Alliance 2996 HPLC (Waters) equipped with a 2476 photodiode array detector. Samples were separated by reverse-phase chromatography on a YMC carotenoid column (particle size 5 μm; 250×4.6 mm) isocratically using a mobile phase of methyl-t-butyl ether:methanol:ethyl acetate (40:50:10, v/v/v) at a flow rate of 1.5 ml/min for 35 min. Peaks were measured at a wavelength from 250-600 nm to facilitate the detection of lycopene.
Production of Lycopene in Y. lipolytica by Expressing the Modified carRP* Genes
For heterologous expressions in Y. lipolytica , two foreign biosynthetic genes (carB and carRP*) and the geranylgeranyl diphosphate synthase (GGPPS) from Y. lipolytica were cloned into Y. lipolytica expression vectors and placed under the control of the strong constitutive promoter TEF as described above. When the three genes were co-expressed in Y. lipolytica , colonies that appeared after 24 hrs incubation were pink. After 4 days growth at 28° C. in YPD liquid medium, HPLC analysis revealed a major peak at 26.6 min ( FIG. 5 ). The peak was identified as lycopene by comparison of retention time and UV spectrum with authentic lycopene ( FIG. 5 , FIG. 6A and FIG. 6B ). The lycopene-producing Y. lipolytica strain carrying the YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP*-TEF-YLGGPPS construct was designated AI-001.
Marker Excision
The AI-001 strain was transformed with a YAL-LEU-Cre plasmid to excise the selectable marker URA3. The cells were cured of the Cre-expressing plasmid by two successive rounds of culturing in YPD medium, and then selected on SD-LEU and SD-URA medium plate to check the loss of URA3 selection marker and YAL-LEU-Cre plasmid. Transformants were also replica plated on YPD plates for isolation. The results showed that more than 80% of the colonies could not grow in the absence of LEU, and 50% colonies could not grow in the absence of URA. The resulting lycopene-producing strain without URA3 marker gene was designated AI-002.
Example 3: Reconstruction of ε-Carotene Biosynthetic Pathway in Y. lipolytica
Expression of Lycopene &Cyclase (LCYe) in Lycopene-Producing Y. lipolytica
Carotenoids with two ε-rings are not commonly found in plants. Romaine lettuce ( Lactuca sativa var. romaine) is one of the few plants known to accumulate large amounts of lactucaxanthin, a carotenoid with two ε-rings. A cDNA encoding lycopene ε-cyclase (SEQ ID NO: 75) from romaine lettuce (LsLCYe; SEQ ID NO: 72) was shown to efficiently convert lycopene into ε-carotene in E. co/i. (Cunningham and Gant, 2000).
A lycopene ε-cyclase from Lactuca sativa (LsLCYE; SEQ ID NO: 83) codon-optimized for expression in Y. lipolytica (SEQ ID NO: 84) was synthesized and amplified using primers LsLCYe-BamHIF (SEQ ID NO: 27) and LsLCYE-KpnIR (SEQ ID NO: 28), and cloned into the BamHI and KpnI restriction sites of the YAL-rDNA-URA3-TEF-XPR2 vector, to generate YAL-rDNA-URA3-TEF-LsLCYE. AI-002 was transformed with the YAL-rDNA-URA3-TEF-LsLCYE plasmid cleaved by NotI, and Ura + colonies were select on SD-URA plates. The resulting strain was designated AI-003. The URA3 marker was then excised using the same procedure described above for the AI-001 strain. The resulting strain lacking the URA3 marker gene was designated AI-004. After 4 days of growth in liquid YPD medium, cells were extracted and analyzed by HPLC.
Extraction and HPLC Analysis of ε-Carotene
Extraction of ε-carotene was as described above for lycopene extraction, except the extraction solution was a mixture of dichloromethane/methanol at a ratio of 25:75 v/v. Cells were lysed by vortexing for 3 min in the presence of 300 μl glass beads. The extract was collected after centrifugation, and the extraction procedure was repeated three times. The HPLC analysis of ε-carotene was performing the same as described for lycopene analysis, except a flow rate of 0.5 ml/min was used.
As shown in FIG. 7 , FIG. 8A and FIG. 8B , HPLC analysis indicates that strain AI-004 produced two major peaks at 10.9 min and 21.6 min. The two peaks were identified as ε-carotene and β-carotene by comparing retention times and the corresponding spectra with published data. The maximum absorption spectrum of ε-carotene is 417 nm, 441 nm and 470 nm, and β-carotene is 433 nm, 458 nm and 489 nm. In this Y. lipolytica system, all lycopene was converted into ε-carotene and β-carotene with the expression of LsLCYe. The ratio of ε-carotene and β-carotene was 8:2 based on area under the peak in expression system.
Example 4: Reconstruction of α-Ionone Biosynthetic Pathway in Y. lipolytica
Carotenoids are cleaved into norisoprenoids by carotenoid cleavage dioxygenases (CCDs) targeting different double bounds on the carotenoid backbone. In plants, CCD1 and CCD4 biosynthesize norisoprenoids that contribute to the flavor and aroma of fruits. In order to produce α-ionone in a Y. lipolytica system, a CCD must have the following characteristics. First, the CCD must be able to cleave ε-carotene. And second, the CCD should not be able to cleave acyclic carotenoids, such as lycopene and phytoene.
A cDNA (DcCCD1; SEQ ID NO: 88) encoding a protein with carotenoid cleavage dioxygenase activity (SEQ ID NO: 92) and capable of cleaving cyclic carotenes to generate α-ionone and β-ionone was identified in carrots. The recombinant DcCCD1 enzyme also does not cleave non-cyclic carotenoids. In order to demonstrate if the enzyme can cleave ε-carotene, an expression construct comprising a codon-optimized nucleic acid fragment (SEQ ID NO: 89) capable of expressing DcCCD1 (SEQ ID NO: 92) was constructed and introduced into the AI-004 strain engineered to accumulate ε-carotene.
Plasmids Construction and Transformation
A cDNA (SEQ ID NO: 89) encoding a protein with carotenoid cleavage dioxygenase activity from carrot, DcCCD1 (SEQ ID NO: 92), was synthesized, codon-optimized for expression in Y. lipolytica , and amplified with primers DcCCD1-BamHIF (SEQ ID NO: 29) and DcCCD1-KpnIR (SEQ ID NO: 30). The amplified product was cloned into the BamHI/KpnI restriction sites of the YAL-rDNA-URA3-TEF-XPR2 vector, to generate YAL-rDNA-URA3-TEF-DcCCD1. The YAL-rDNA-URA3-TEF-DcCCD1 construct was linearized with NotI, and used to transform AI-004. Ura + colonies were selected on SD-URA plate, and were designated AI-005. Single colonies were selected and were used to inoculate 3 ml YPD liquid medium, and were incubated at 28° C. with shaking at 250 rpm. An overnight culture (1 ml) was used to inoculate 50 ml YPD medium in 250 ml tightly closed rubber stopper flask for HS-SPME.
Solid Phase Microextraction (SPME), HPLC and GC-MS Analysis
The headspace from the overnight cultures above was sampled with a 75-μm Carboxen/Polydimethylsiloxane (CAR/PDMS) fiber for one hour at room temperature (Cat No. 57344-U Sigma, St Louis, Mo., USA). Samples were analyzed on a DB-1 column (12.5 m, 0.2-mm inner diameter, 0.33-μm methyl silicone film coating, from P. J. Cobert, St. Louis, Mo.). After 4 days of growth in liquid YPD medium, a SPME fiber was pulled into the needle sheath and introduced into the flask, and headspace volatiles were allowed to absorb to the fiber at room temperature for 30 min. Subsequently, the SPME device was removed from the flask and inserted into the injection port of the GC system. The volatile compounds collected from the headspace were analyzed using gas chromatography-mass spectrometry (GC-MS; Agilent Technologies 6890N capillary GC and 5973N Network Mass Selection Detector, Foster City, USA) at the Washington University Biomedical Mass Spectrometry Research Resource. Identification of α-ionone was performed by comparison of mass spectra and retention time data to authentic standard and supplemented with GC-MS library.
As shown in FIG. 9 , the expression of DcCCD1 led to the expected de-coloration of the orange Y. lipolytica strain having accumulated ε-carotene. Loss of color indicated that ε-carotene was metabolized to colorless compounds. HPLC analysis indicated that the ε-carotene and β-carotene peaks were disappeared, and were replaced with two new peaks at 5.2 min and 5.8 min ( FIG. 10 ). The UV spectra of the compound at the 5.2 min peak exhibited absorption maxima at 395 nm, 419 nm and 446 nm ( FIG. 11 ). The spectrum of the peak labeled as C14-dialdehyde (rosafluene dialdehyde) was consistent with the previously described C14-dialdehyde. The peak at 5.8 min is the product of β-carotene cleavage, and due to the instability of C14 dialdehyde, it may be a degradation product of C14-dialdehyde.
SPME-GC-MS analysis of the headspace of cultures Y. lipolytica cultures expressing DcCCD1 revealed the presence of α-ionone ( FIG. 12 ), as evidenced by its retention time and a mass spectrum identical to that of authentic α-ionone ( FIG. 13 ).
Example 5: Intron-Containing TEF Promoter (TEFIN) Increases α-Carotene and Lycopene Production in Y. lipolytica
The XPR2 promoter (pXPR2) has been identified as one of the strongest promoters in Y. lipolytica . However, its complex regulation hindered its industrial applications. The functional dissection of pXPR2 revealed that one of its upstream activating sequences (UAS) can increase the expression levels of promoters. Four tandem UAS1B copies were fused to a minimal LEU2 promoter to obtain a strong constitutive promoter independent from environmental conditions that normally regulate the XPR2 promoter. Subsequently, a series of strong constitutive promoters for translation elongation factor-1α (pTEF1), ribosomal protein S7 (pRPS7), export protein (pEXP1) were identified. The hrGFP reporter gene was used to evaluate the promoter strengths of endogenous Y. lipolytica . The results showed that pEXP1 was the strongest, followed by pTEF1 promoter among seven tested endogenous promoters in yeast synthetic complete medium (YSC) containing 20 g/I glucose. Recently, it has been reported that an intron-containing TEF1 promoter increased gene expression 17-fold over the intron-less TEF1 promoter (for example, see Tai et al., (2013) Metabolic Engineering, 15:1-9).
Construction of Intron-Containing TEF Promoter (TEF1N)
TEFIN promoter was amplified by PCR with primers TEF-EcoRI-PmeIF (SEQ ID NO: 3) and TEFIN-BamHI-SnaBIR (SEQ ID NO: 57), and the amplification product was cloned into the EcoRI/BamHI restriction sites of the YAL-rDNA-URA3-TEF-XPR2 plasmid, resulting in the YAL-rDNA-URA3-TEFIN-XPR2 vector.
For lycopene biosynthesis, three genes, OptcarB, OptcarRP*, and GGPPS, were amplified with primers OptcarB-SnaBIF (SEQ ID NO: 39)/OptcarB-AvrIIR (SEQ ID NO: 18), OptcarRP*-SnaBIF (SEQ ID NO: 40)/OptcarRP*-AvrII (SEQ ID NO: 20), and YLGGPPS-SnaBIF (SEQ ID NO: 22)/YLGGPPS-AvrIIR (SEQ ID NO: 23), respectively. The digested amplification products were then cloned into the SnaBI/AvrII restriction sites of the YAL-rDNA-URA3-TEFIN-XPR2 vector to form the plasmids YAL-rDNA-URA3-TEFIN-OptcarB, YAL-rDNA-URA3-TEFIN-OptcarRP* and YAL-rDNA-URA3-TEFIN-YLGGPPS, respectively. Finally, the three-gene expression cassette vector, YAL-rDNA-URA3-TEFIN-OptcarB-TEFIN-OptcarRP*-TEFIN-YLGGPPS, was generated using the same strategy used for generating the YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP*-TEF-YLGGPPS vector described above. For β-carotene biosynthesis, the same YAL-rDNA-URA3-TEFIN-OptcarB-TEFIN-OptcarRP*-TEFIN-YLGGPPS vector was used, with the exception that the OptcarRP* gene was replaced with the OptcarRP gene. The YAL-rDNA-URA3-TEFIN-OptcarB-TEFIN-OptcarRP*-TEFIN-YLGGPPS for lycopene production and YAL-rDNA-URA3-TEFIN-OptcarB-TEFIN-OptcarRP-TEFIN-YLGGPPS for β-carotene production were transformed into Y. lipolytica to generate AI-005 and AI-006 strains, respectively. The two strains with the URA3 marker gene removed were designated AI-007 and AI-008.
Measurement of β-carotene and lycopene using spectroscopy analysis
Relative concentration of β-carotene and lycopene was measured with a simple and rapid UV-Vis spectrometric method using a NanoDrop 2000 UV-Vis spectrophotometer (Thermo Scientific, Wilmington, Del.). The spectra of β-carotene and lycopene were set at 460 nm and 502 nm, respectively.
As shown in FIG. 14 and FIG. 15 , intron-containing TEFIN promoter increased the accumulation of lycopene and β-carotene in Y. lipolytica . Spectrometric analysis indicated that the production was increased by 3-fold for lycopene (UV-Vis absorbance value of 0.153±0.024 vs 0.472±0.032) and 1.6-fold (0.358±0.051 vs 0.583±0.061) for β-carotene.
Example 6: Expression of FPPS::GGPPS Fusion Protein Increases α-Carotene and Lycopene Production in Y. lipolytica
It has been reported that fusing FPPS to GGPPS increases geranyl geraniol and bisabolene production in Saccharomyces cerevisiae . However, Y. lipolytica is a dimorphic yeast, phylogenetically very distant from the model yeast S. cerevisiae . Additionally, Y. lipolytica possesses a larger genome (20 Mbp vs. 10 Mbp) with a lower overall gene density than S. cerevisiae . In order to determine if fused FPPS to GGPPS of Y. lipolytica also increases the production of carotenoid, precursors of ionones, FPPS to GGPPS of Y. lipolytica were fused, separated by a four amino acid linker.
Reconstruction of β-Carotene Biosynthetic Pathway in Y. lipolytica
The β-carotene biosynthetic pathway was reconstructed using the same strategy described above, wherein the wild-type bifunctional lycopene cyclase/phytoene synthase (carRP; SEQ ID NO: 63) replaces the modified carRP* (SEQ ID NO: 66). The resulting plasmid YAL-rDNA-URA3-TEF-OptcarB-TEF-OptcarRP-TEF-YLGGPPS was transformed into Y. lipolytica , to generate the 3-carotene-producing strain designated AI-009. The strain with the URA3 marker gene removed was designated AI-010. Extraction of β-carotene was as described above for ε-carotene.
Fusion of FPPS and GGPPS with PCR
To construct the FPPS::GGPPS fusion gene, the stop codon of FPPS (SEQ ID NO: 72) was removed and a nine amino acid linker (Gly-Gly-Gly-Ser) was introduced between the open reading frame of FPPS and GGPPS via two-rounds PCR strategy yielding the fusion gene of FPPS::GGPPS (SEQ ID NO: 73). One PCR was carried out with forward primer of YIFPPS-BamHIF (SEQ ID NO: 31) and reverse primer of YIFPPS-GGPPS-R (SEQ ID NO: 33), and another PCR was performed with primers YIFPPS-GGPPS-F (SEQ ID NO: 34) and YIGGPPS-AvrIIR (SEQ ID NO: 23). The genomic DNA of Y. lipolytica was used as a template. Each PCR product was purified and used as a template for stitching the amplification fragments in a second round of PCR amplification, using primers YIFPPS-BamHIF (SEQ ID NO: 31)/YIGGPPS-AvrIIR (SEQ ID NO: 23) and YIFPPS-SnaBIF (SEQ ID NO: 32)/YIGGPPS-AvrIIR (SEQ ID NO: 23). This resulting 2.04 kb fusion product was inserted into the expression vector YAL-rDNA-URA3-TEF-XPR2 at the BamHI and AvrII sites and YAL-rDNA-URA3-TEFIN-XPR2, yielding YAL-rDNA-URA3-TEF-FPPS::GGPPS and YAL-rDNA-URA3-TEFIN-FPPS::GGPPS. The resultant plasmid was confirmed using restriction enzyme digestion and sequencing. The YAL-rDNA-URA3-TEF-FPPS::GGPPS vector was transformed into lycopene and β-carotene-producing strains AI-002 and AI-010, and the YAL-rDNA-URA3-TEFIN-FPPS::GGPPS vector was introduced into lycopene and β-carotene-producing strains AI-007 and AI-008.
As shown in FIG. 14 and FIG. 15 , the expression of the FPPS::GGPPS fusion protein (SEQ ID NO: 74) increased the accumulation of lycopene and β-carotene in Y. lipolytica . Spectrometric analysis indicated that expression of FPPS::GGPPS fusion gene increased lycopene and β-carotene production in Y. lipolytica by up to 4-fold (UV-Vis absorbance value of 0.153±0.024 vs 0.608±0.046) for lycopene, and 2-fold (0.358±0.051 vs 0.721±0.082) for β-carotene.
Example 7: Reconstruction of β-Ionone Biosynthetic Pathway in Y. lipolytica
As described above, the cleavage reactions of carotenoids are generally catalyzed by a class of non-heme iron enzymes known as carotenoid cleavage dioxygenases (CCDs). In plants, CCDs are generically grouped into five subfamilies according to cleavage position and substrate preference. The carotenoid cleavage dioxygenase family 1 (CCD1) cleaves β-carotene at 9, 10 and 9′10′ double bonds, generating β-ionone. Many CCD1 genes have been cloned and characterized from different plants, such as Arabidopsis , tomato, crocus, petunia , and carrot. As mentioned above, a nucleic acid sequence (SEQ ID NO: 88) encoding a protein with carotenoid cleavage dioxygenase activity, DcCCD1 (SEQ ID NO: 92), was identified in carrot. DcCCD1 cleaves cyclic carotenes to generate α-ionone and β-ionone. In order to demonstrate if the enzyme can cleave β-carotene, the DcCCD1 expression vector (YAL-rDNA-URA3-TEF-DcCCD1) was constructed and introduced into the Y. lipolytica strain engineered to accumulate β-carotene (AI-010). As shown in FIG. 16 , the expression of DcCCD1 led to the expected decoloration of the accumulated orange β-carotene Y. lipolytica strain (AI-010), which was absent in control expressing the empty vector.
Example 8: Production of Lycopene in Saccharomyces cerevisiae
The S. cerevisiae strain WAT11 (MATa; ade2-1; his3-11, -15; leu2-3,-112; ura3-1; canR; cyr+) was grown at 28° C. with shaking at 250 rpm in YPD medium (10 g/L yeast extract, 20 g/L peptone and 20 g/L glucose) or in SD-dropout medium containing 1.7 g/L yeast nitrogen base without amino acids and ammonium sulfate, 20 g/L D-glucose, 5 g/L ammonium sulfate, 2 g/L yeast synthetic drop-out medium supplements (US biological, Swampscott, Mass.). Depending on the nutrient requirement of strains, 20 mg/L histidine, 100 mg/L leucine, 50 mg/L tryptophan or 40 mg/L uracil may be added to the medium. 20 g/L agar may be used for plates.
Construction of Lycopene Biosynthetic Pathway Plasmids
The pathway of lycopene biosynthesis in S. cerevisiae was reconstituted by over-expressing three enzymes: phytoene dehydrogenase (SEQ ID NO: 61) from Mucor circinelloides (carB; SEQ ID NO: 60) and modified bi-functional lycopene cyclase/phytoene synthase (SEQ ID NO: 69) from Mucor circinelloides (carRP*; SEQ ID NO: 68), the genes of both of which were codon-optimized for expression in S. cerevisiae , truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase (tHMG1; SEQ ID NO: 82) encoded by SEQ ID NO: 81, and farnesyl pyrophosphate synthase (SeERG20; SEQ ID NO: 76 encoded by SEQ ID NO: 75)::geranylgeranyl diphosphate synthase (SeGGPPS; SEQ ID NO: 78 encoded by SEQ ID NO: 77) fusion gene (SeERG20::SeGGPPS SEQ ID NO: 80) from S. cerevisiae encoded by SEQ ID NO: 79. The carB and carRP* genes codon-optimized for expression in S. cerevisiae were cloned and expressed in S. cerevisiae . The four genes, carB, caRP*, SeERG20::SeGGPPS and tHMG1, were amplified by PCR using the primers, SecarB-EcoRIF (SEQ ID NO: 41)/SecarB-BglIIR (SEQ ID NO: 42), SecarRP*-BamHIF (SEQ ID NO: 43)/SecarRP*-XhoIR (SEQ ID NO: 44), SetHMG1-EcoRIF (SEQ ID NO: 45)/SetHMG1-SpeIR (SEQ ID NO: 46), and SeERG20::SeGGPPS-BamHIF (SEQ ID NO: 47), SeERG20::SeGGPPS-XhoIR (SEQ ID NO: 48), respectively. The carB and carRP* genes were placed under the control of the GAL10 and GAL1 promoters in the pESC-TRP yeast expression vector, respectively, to form the plasmid pESC-TRP-carB-carRP*. The tHMG1 gene was cloned into the EcoRI/SpeI sites of the pESC-HIS to yield pESC-HIS-tHMG1. Then the SeERG20::SeGGPPS was cloned into the BamHI/XhoI site of pESC-HIS-tHMG1 to yield pESC-tHMG1-SeERG20::SeGGPPS.
Expression of Lycopene Biosynthetic Pathway Genes in S. cerevisiae
S. cerevisiae Wat11 was transformed with pESC-TRP-carB-carRP* and pESC-HIS-tHMG1-SeERG20::SeGGPPS, and the transformants were screened on SD-Trp-His agar plate. Single colonies were cultured in SR medium (0.67% yeast nitrogen base, 2% raffinose, 0.2% complete supplement mixture) that lacked tryphtophan and histidine. The medium further included 2% galactose for inducing expression of genes introduced downstream of GAL1 and GAL10 promoters. The cultured cells were collected by centrifugation, and the cell pellets were re-suspended in extraction solution (methyl-t-butyl ether:methanol:ethyl acetate (40:50:10)). The cell suspension was lysed using 300 μl of 425-600 μm diameter glass beads for 3 min with a vortex mixer. The extract was collected after centrifugation, and the supernatant was analyzed by HPLC.
Example 9: Reconstruction of ε-Carotene Biosynthetic Pathway in S. cerevisiae
The codon-optimized lycopene ε-cyclase from Lactuca sativa (LsLCYE; SEQ ID NO: 85) was synthesized and amplified with primers, Se-LsLCYe-BamHIF (SEQ ID NO: 49)/Se-LsLCYE-XhoIR (SEQ ID NO: 50) and cut by BamHI and XhoI. Then, the digested fragment was cloned into BamHI/XhoI-digested vector pESC-LEU, to form pESC-LEU-LsLCYE. Strain carrying plasmid pESC-TRP-carB-carRP* and pESC-HIS-tHMG1-SeERG20::SeGGPPS were transformed with pESC-LEU-LsLCYE plasmid, and Trp + His + Leu + colonies were selected on SD-Trp-His-Leu plate. After incubation in liquid SD medium, the pellets were suspended in extraction solution (dichloromethane/methanol, 25:75, v/v) and analyzed by HPLC.
Example 10. Reconstruction of α-Ionone Biosynthetic Pathway in S. cerevisiae
Plasmids Construction
DcCCD1, carotenoid cleavage dioxygenase of carrot was codon-optimized (SEQ ID NO: 90) for expression in S. cerevisiae , and amplified with primers SeDcCCD1-EcoRIF (SEQ ID NO: 53) and SeDcCCD1-BglIIR (SEQ ID NO: 54). The amplification product was then cloned into the EcoRI/BglII restriction sites of the pESC-URA vector, to form pESC-URA-DcCCD1. The S. cerevisiae strain harboring pESC-TRP-carB-carRP*, pESC-HIS-tHMG1-SeERG20::SeGGPPS and pESC-LEU-LsLCYE was transformed with pESC-URA-DcCCD1, and Trp + , His + , Leu + and Ura + colonies selected on SD minus four amino acids plate.
Solid Phase Microextraction (SPME), HPLC and GC-MS Analysis
The same procedures was applied to grow and induce gene expression as described above. The headspace was sampled with a Carboxen/Polydimethylsiloxane (CAR/PDMS) fiber for one hour at room temperature. The volatile compounds collected from the headspace were analyzed using gas chromatography-mass spectrometry. Identification of α-ionone was performed by comparison of mass spectra and retention time data to authentic standard and was supplemented with GC-MS library.
Example 11. Production of α-Ionone and β-Ionone in E. coli
Bacterial Strains and Plasmids
E. coli C2984 and BL21 (DE3) (New England Biolabs, Ipswich, Mass.) were used for cloning and recombinant protein expression. Plasmid pETDuet-1, and pCOLADuet-1 were used for recombinant protein expression purposes.
Construction of Plasmid for β-Carotene and ε-Carotene Synthesis
The pAC-BETA and pAC-LYC plasmids was used to produce β-carotene and lycopene, respectively. The pAC-BETA plasmid contains all of the genes required for the synthesis of β-carotene, including crtE [GGPP (geranylgeranyl pyrophosphate) synthase], crtB (phytoene synthase), crtI (phytoene desaturase) and crtY (lycopene cyclase) from Erwinia herbicola ], and retains a chloramphenicol resistance gene (Cunningham et al., Plant Cell, 8: 1613-1626, 1996). Plasmid pAC-LYC is a pACYC184 derived vector containing functional carotenoid biosynthesis genes for geranylgeranyl pyrophosphate synthase (crtE), phytoene synthase (crtB), and phytoene desaturase (crtI) from Erwinia herbicola , and also contains a chloramphenicol resistance gene (Cunningham et al., Plant Cell, 6: 1107-1121, 1994). E. coli colonies containing pAC-LYC accumulate lycopene.
The LsLCYE gene fragment was synthesized and amplified by PCR using the primers EcLsLCYE-BamHIF (SEQ ID NO: 51) and EcLsLCYE-PstIR (SEQ ID NO: 52). The purified LsLCYE gene fragment was excised using BamHI and PstI, followed by insertion into the corresponding sites of the vector pETDuet-1 to create pETDuet-LsLCYE. The plasmid pETDuet-LsLCYE, extracted from the colony with the positive insert and confirmed by sequencing, was transformed into E. coli BL21 (DE3) containing the plasmid pAC-LYC for protein expression and production of ε-carotene.
Construction of plasmid for α-ionone and β-ionone synthesis
The DcCCD1 gene fragment was synthesized and obtained by PCR using the primers EcDcCCD1-EcoRIF (SEQ ID NO: 55) and EcDcCCD1-PstIR (SEQ ID NO: 56). The purified DcCCD1 gene fragment was digested by EcoRI and PstI, followed by insertion into the corresponding sites of the vector pCOLADuet-1 to create pCOLADuet-DcCCD1. Subsequently, the plasmid pCOLADuet-DcCCD1 was transformed into BL21 (DE3) containing pAC-BETA for production of β-ionone and transformed into BL21(DE3) harboring pAC-LYC and pETDuet-LsLCYE for production of α-ionone.
Shake Flask Cultures and Growth Conditions
E. coli BL21(DE3) containing pAC-BETA and pCOLADuet-DcCCD1 was grown in the LB medium with 34 mg/L chloramphenicol and 50 mg/L kanamycin to OD600=0.6 in a shaker at 37° C., and then changed to 30° C. with addition of lactose to a final concentration of 1.5% (w/v) to induce the expression of DcCCD1 and further incubated at 30° C. E. coli BL21(DE3) containing pAC-LYC, pETDuet-LsLCYE and pCOLADuet-DcCCD1 was grown in the LB medium with 34 mg/L chloramphenicol, 100 mg/L ampicillin, and 50 mg/L kanamycin to OD600=0.6 in a shaker at 37° C., and then changed to 30° C. with the addition of lactose to final concentration of 1.5% (w/v) to induce the expression of LsCYE and DcCCD1. The culture was kept shaking under the same culture condition, and samples were taken at intervals for GC-MS analysis as mentioned above.
All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.
Although the disclosure described herein is susceptible to various modifications and alternative iterations, specific embodiments thereof have been described in greater detail above. It should be understood, however, that the detailed description is not intended to limit the disclosure to the specific embodiments disclosed. Rather, it should be understood that the disclosure is intended to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure as defined by the claim language.